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Durant la derniere decennie nous avons assiste a une explosion de donnees
genomiques sequentielles provenant de projets publiques et prives. Le sequence
complete du genome humain a ete publiee ainsi que la localisation certains genes a
ete tracee pour des chromosomes individuels.
Avec I'accroissement de I'information sequentielle, I'industrie de la biotechnologie
s'est serieusement etablie. Le brevets octroyes en regard des genes a joue un role
important dans cette industrie, aussi il y a eu une augmentation dans la demande de
brevets dans Ie domaine du materiel genetique humaine. Cependant apres plusieurs
controverses publiques et la creations de regles internationales certains doutes ont ete
souleves a propos de la «brevetabilite »du genome humain, mais impact. II sera
question dans notre etude ces inquietudes, de la reponse a ces inquietudes par les
bureaux des brevets differentes juridictions, ainsi que des divers moyens utilises pour
de ces problemes tout en avan<;ant Ie present debat en utilisant les structures legales
existantes.
Summary
Keywords: biotechnology, patentability, patent law, human genetic material, and
china.
II
The past decade has seen an explosion in the availability of genome sequence data
from public and private genome projects. Most notably, the complete human DNA
genome sequence has been published and the locations of some of the genes have
been mapped to individual chromosomes.
Commensurate with the growth in sequence information, the biotechnology industry
has become firmly established. Gene patents have played an important part in
this industry, and there has been a marked increase in patent applications
filed in the field of human genetic resource. However, concerns have been
raised over the patentability of human genetic material through public
protests and international statements, but to little effect. Discussed here are
some of these concerns, the patent office's response to them in
different jurisdictions, and ways in which to address these issues and
to move the debate forward within current legal structures.
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Introduction
In the early 1980s, biotechnology was applied commercially in producing diagnostics and
therapeutics. Biotechnology companies were created specifically to exploit the
commercial potential of biotechnology. Ever since the Chief Justice of the U.S. Supreme
Court, Warren Earl Burger ruled that "everything under the sun made by man"i was
patentable, genetic engineering has been fuelling the growth of the biotechnology
industry. Public markets recognized the potential benefits of biotechnology and money
flowed into biotechnology companies. However, the concomitant patenting of the
resulting products, especially human based products, has stimulated debates.
During the past twenty years, patent law has struggled to keep pace with the rapid growth
of research and developments in the field of biotechnology. Not surprisingly, science has
outpaced the law, which is playing catch-up when it comes to providing patent protection
for biotech inventions. Facing increasing debates and issues around patenting of biotech
inventions involving human genetic materials, international communities and nations
have tried to harmonize patent law.
In the United States of America, the United States Patent and Trademark Office's
(USPTO) policy has been more lenient on patenting scopes and standards than other
countries. It conferred very extensive protection on patents on human genes, with
i Diamond v. Chakrabarty, 447 U.S.303, 206 U.S.P.Q. 193 (1980).
11
exceptions granted only for ' laws of nature, physical phenomena or abstract ideas'. ii
Nevertheless, while early U.S. patents on biotech inventions often included seemingly
broad, "prophetic" claims, for 20 years now, the Court has gradually narrowed the scope
of biotech patents. iii
In Europe, a legal framework has been created by the European Patent Convention (EPC)
and European Union Directive for the Legal Protection of Biotechnological Inventions
(B.U. Directive) for applicants in the field of biotechnology. Most European countries
have now grasped the nettle of implementation of the Directive, and are drafting
legislation to incorporate its provisions into national patent law. The EPC and the
Directive ensure that biotechnology patent law is both strong and consistent across
Europe. In this way, European consumers and biotech companies are not disadvantaged
with respect to their American and Japanese counterparts.
Canada takes an intermediate stance on patentability of human genetic materials. The
Canadian Patent Office is reluctant to grant patents on life forms. As we will see, there
have only been a handful of judicial cases dealing with genetic materials in Canada.
Neither human beings nor their organs are patentable, but products derived from the
human body, including cell lines, genes, and DNA sequences are patented.
ii USPTO interpreted the Court ruling of Diamond v. Chakrabarty, which defined a number of elements in
order to test patentability under section 101. See "This Opinion Was Not Written For Publication" by
YSPTO (1997), online: http://www.uspto.gov/web/offices/dcomfbpai/decisions/fd970777.pdf.at 5.
III See Amgen Inc v. Chugai Pharmaceutical Co. Ltd. and Genetics Institute, 927 F. 2d 1200, 18 U.S.P.Q.
2d 1016 (Fed. Cir. 1991). The ruling prevented a company from getting very broad-based claims on all
DNA sequences that code for a protein or analogs of that protein. See also Fiers v. Revel, 984F.2dll64,25
U.S.P.Q. 2d 1601 (Fed. Cir. 1993); See also Regents ofthe University of California v. Eli Lilly & Co., 119
F.3d 1559, 43 U.S.P.Q. 2d 1398(Fed. Cir. 1997), in which the Court repeated: "Accordingly, an adequate
written description of a DNA requires more than a mere statement that it is part of the invention and
reference to a potential method for isolating it; what is required is a description of the DNA itself."
iii
As the only member from the developing countries in the human genome project (HGP)
consortium, China faces the same issue of patentability on human genetic materials. In
contrast to the broad patent scope of U.S.A., China is extremely strict in examining gene
patent applications. So far, there is no re-examination of board decisions or court
decisions relating to the novelty, utility and inventive step of gene-related inventions.
This is because there is also no related provision in the Examination Guidelines of the
Chinese Patent Office. However, China seems inclined to patent human genetic materials
in the immediate future.
This paper will start with a preliminary chapter on an introduction of the molecular
biology of genes, followed the legal status of human genetic material is described in
chapter II. Next, the controversy and the requirements of patenting of genes will be
respectively discussed in chapter III and chapter IV. The detailed overview of the
international law on the patenting of genes will be exposed in chapter V. This will be
followed by chapter VI, which outlines the legal framework in the U.S.A., Europe,
Canada, and China, as concerns the patentability of biotech inventions derived from
human resources. Last but not least, a comparative study on the requirements for
patenting human genetic material will be examined in light of current American and
Chinese national laws in chapter VII. The concluding remarks provide a suggestion that
China should adopt patent protection on biotech inventions related to human genetic
materials.
11. Preliminary Chapter: Scientific and Socio-Economic Issues
An understanding of how the patent system differentially treats the patenting of human
genes necessitates an understanding of the molecular biology of genes. This
preliminary chapter explains the evolution and the biology behind genes, describing
what a gene is and what a gene does.
i. Evolution and genetics
The publication in 1859 of The Origin of Species by Charles Darwin ushered in a new
era in intellectual history. It radically changed our conception of the universe and our
place in it. Darwin completed the Copernican revolution by drawing out for biology the
ultimate conclusion from the notion of nature as a lawful system of matter in motion.
The adaptations and diversity of organisms, the origin of novel and highly organized
forms, even the origin of man himself could now be explained by an orderly process of
change governed by natural laws.
In the Origin of Species, Darwin proposed that evolution occurs by natural selection:
individuals in a species differ in their heritable fitness for a particular environment. The
fittest have more surviving progeny.! These steps, accumulating in successive
generations, eventually led to the formation of new species. But while Darwin
presented a mass of evidence for this theory of natural selection, he barely discussed an
equally important part of his theory: the requirement for a continuous supply of
heritable novelty for natural selection to act on. The reason for his neglect is that the
1 As discussed in B. D. Davis, The Genetic Revolution (Baltimore and London: The Johns Hopkins
University Press, 1991) at 13.
2mechanism of this postulated variation was entirely unknown, for there was not yet any
science of genetics.2
Until about the mid-twentieth century, modern biology corroborated Darwin's view of
biological evolution and added depth and infinitely more detail to our understanding of
the processes. Darwin's theory of natural selection assumes that hereditary variation is
pervasive. It is genetics that eventually filled the gap accounting for the origin of
hereditary novelty.
Since 1950s, developments in molecular biology have made biologists able to research
biological evolution at the molecular level. Because the molecular structure of the
different species is not identical, their relationships can be determined by means of
analyzing the molecular structure. Take the example of the comparision of the
arrangement of the amino acid of the peptide chain in the hemoglobin molecules
between three species: human, ape and horse; human and ape are identical on the
arrangement of amino acid, however, there are 86 differences between that of the
human and the horse.3 Cytochrome c molecule is the protein molecule necessary for the
oxidization food. Scientists have determined and compared the molecular structure of
cytochrome c among hundreds of species. The results indicate that the more familiar
the molecular structure is, the closer the species relationship is.
This molecular evolution is greatly enriching evolutionary biology. Biologists have
found that all living things use deoxyribonucleic acid (DNA) to pass traits on to their
2 Ibid., at 13.
3 Z.L. Chen and D. Ming, Copying Lives: Human Beings and Clone (Beijing: Popular Science Press,
1999), at 51.
3offspring.4 The DNA structure is referred to as the double helix and resembles a
spiraled ladder. Each rung of the ladder consists of a pair of nucleotide bases. These
bases are the structural unit of DNA, and are as follows: Adenine, Thymine, Guanine
and Cytosine (A, T, G and C respectively). On this ladder, "A" may link only with "T"
to form a rung, and "G" may only link with "C". While an entire DNA molecule
consists of only four types of nucleotide bases, the vast diversity and complexity of life
is achieved through the extreme length and exact sequencing of the rungs.s The human
DNA complex may consist of as many as 3 billion base pairs.6
The path from the DNA code to the expression of the corresponding genetic trait is
complex. DNA is organized into units called genes. A gene typically codes for a single
protein, and it is this protein that effects the genetic traits. For instance, many genes
code for proteins that function as enzymes, which facilitate biochemical reactions in the
human body. These biochemical reactions ultimately result in the expression of a
genetic trait, and in the case of defective genes, disease.
ii. Genetic Manipulation
All living things are made up of cells that are programmed by the same basic genetic
material, called DNA. Genes are working portions of DNA and the biological units of
heredity. DNA is the chemical database that carries the complete set of instructions for
making all the proteins a cell will ever need, which in essence, determine every detail
4 M. S. McBride, "Patentability of Human Genes: Our Patent System Can Address the Issues Without
Modification", (2002) 34 in K. B. Tripp, ed., Intellectual Property Law Review (New York: Clark
Boardman Co.), at 251.
5 K. Gerald, Cell and Molecular Biology (New York: John Wiley & Sons, Inc., 1996), at 410 - 411.
6 L. Walters and J. G. Palmer, The Ethics ofHuman Gene Therapy (New York: Oxford University Press,
1997), at 5.
4about an organism. Specific genes code for specific traits that are found in a given
organism. For example, one gene may code for eye color while another one may code
for shoe size.
DNA is an extremely complicated biological system. The many thousands of proteins
coded for by the DNA must work precisely with other proteins in order to insure the
sound health of a person. This precise interaction of proteins in tum dictates such things
as physical appearance, general health, and metabolism. In past twenty years,
physicians and geneticists have made a great progress on treating genetic disease based
on the development on molecular genetics. Increasingly, genetic manipulation is used
in clinical medicine and the life sciences.
Genetic manipulation has many meanings, depending on who is using the term. It has
also been called genetic engineering, biomanipulation, and biological engineering.?
Engineering can be defined as the application of scientific principles to practical ends.
The modem era of genetic engineering began in 1973 with the first successful
experiment to recombine DNA from one organism with that of another by Dr. Herbert
Boyer and Stanley Cohen.
a. Genetic Mutations and Disease
Many diseases stem from a defect in the genetic code. Mutations upset the delicate
balance of proteins in the human body. There are two ways to receive a genetic defect
or mutation. A mutation can be inherited from one or both parents. In this case, every
cell in this person will have the mutation in its DNA. Or a genetic mutation can be
7 A. S. Moraczewski, eds., Genetic Medicine and Engineering-Ethical and Social Dimensions (St-
Louis: The Catholic Health Association of the United States and The Pope John XXIII Medical-Moral
Research and Education Center, 1983), at 145.
5acquired, in which case only the cells which arise from the originally affected cell will
have the mutation.8 Acquired mutations can occur for a number of reasons, possibly as
a result of carcinogens or toxins. Acquired mutations occur largely during DNA
replication. Sometimes the cell's safeguards against mutations grow less efficient with
age. In any event, a minute change in DNA may have disastrous repercussions.
b. Gene Therapy
Gene therapy is the process by which cells are supplied with healthy copies of missing,
flawed, or desirable genes. Gene therapy holds the promise of curing disease and
improving the quality of life, target indications for gene therapies include genetic and
metabolic diseases, cancer, acquired diseases such as AIDS, and cardiovascular
disease.9 The first clinical trial was initiated in 1990.10 Current gene therapy is
considered as a novel approach in its very early stage and is primarily experimentation
based, with a few early human clinical trials. The field of gene therapy continues to
focus its efforts on patients with severe and life-threatening diseases who usually have
few treatment options or who have failed all available therapies.
There are two types of gene therapy: somatic and germ line. Somatic gene therapy
treats specific types of target cells and alters the DNA of these cells. For example,
somatic gene therapy may be used to treat some sort of genetic defect in the lung.
8 Chen and Ming, supra note 3, at 190 to 196.
9 Davis, supra note 1, at 144 to 145 .
10 On September 14, 1990, the first officially sanctioned human somatic-cell gene-therapy experiment
began on a 4-year-old girl. See Walters, supra note 6, at 17.
6Somatic gene therapy however has to be done continually, since cells will eventually
die, and the treatment won't necessarily spread. II
Germ line therapy might eventually permanently and heritably treat some diseases by
modification of the genes in fertilized egg and sperm cells. The process has already
been carried out, albeit with some technical difficulty, in lower mammals. 12 If this
approach were to become technically and ethically feasible in human beings, a single
genetic modification might prevent disease not only in specific individuals but also in
all of their offspring. However, germ line therapy has been criticized more than somatic
cell therapy, on both technical and moral grounds. 13
c. Xenotransplantation
The demand for human organs for transplantation continues to far outstrip the available
supply. The United Network of Organ Sharing (UNOS) in U.S.A. found that, from
1988 to 1994, the waiting list of patients in the United States for organ transplants grew
from 16,026 to 37,609, increasing at a rate of 22.4 percent per year. 14 By the end of
1998, about 60,000 people were registered on transplant waiting lists. Unfortunately,
each year, less than one-third of the listed people received solid organ transplants. 15
However, modified organs from other species are believed to be promising sources for
11 J. M. Wilson, "Human Gene Therapy: Present and Future."(l999) online: Human Genome News <
http://www.ornl.gov>.
12 Davis, supra note 1, at 146.
13 For example, germ line therapy has the potential to affect not only the individual being treated, but his
or her children as well. Germ line therapy would also change the genetic pool of the entire human species
and future generations would have to live with that change. On ground of ethics, public think that we are
not wise enough to know which human traits can be modified without dire social or evolutionary
consequences.
14 Institute of Medicine, Committee on Xenograft Transplantation, "<setting the stage> in
Xenotransplantation : Science, Ethics and Public Policy, in B. M. Knoppers, ed. Droit, Biotechnologies et
Societe (Medecine Moderne) (Montreal: COOP DROIT, Universite de Montreal, 2002)863, at 865.
15 Biotechnology Industry Organization (BIO), Encouraging Development of the Biotechnology Industry:
A Best Practices Survey of State Efforts (2000), online: BIO <http://www.bio.org/govtJethics.html>.
7donor organs for humans. This practice is called xenotransplantation. The
transplantation has been found to be an especially effective, cost-efficient treatment for
severe, life-threatening heart, kidney, lung and other diseases. The first xenotransplant
experiment was conducted in 1905. Between late 1963 and early 1964, a team at Tulane
University led by Keith Reemtsma transplanted kidneys from chimpanzees into SIX
patients, one of whom lived for nine months. 16
The most significant obstacle to xenotransplantation is the human body's immune
system protections against infection. When tissue not recognized as human is
introduced into the body, hyperacute rejection occurs -- the body cuts off the flow of
blood to the donated organ. The most promising method for overcoming hyperacute
rejection is believed to be genetic modification. By inserting human genetic material
into other donor animals, it is believed that the human body will recognize the new
organ as human and begin to use it as its own. 17 Several biotechnology companies are
working to overcome hyperacute rejection and other obstacles to xenotransplantation.
d. Human Genetic Project
Genetic material is housed on chromosomes. In humans, there are 23 pairs of
chromosomes. Genes are located in a definite position on a particular chromosome.
When a doctor suspects that a certain gene may be the reason for a problem, obviously
this gene must be located, before any problem can be remedied. Such is the goal of the
Human Genome Project (HGP). The HGP that was initiated in 1990 is a world wide
16 Supra note 14, at 864.
17 Supra note 15.
8research activity and many countries are playing a role in mapping the gene. IS It was
expected to take between fifteen and twenty years. The goal of the HOP is to map and
sequence the 24 different human chromosomes (22 autosomes and the two sex
chromosomes, X and Y). This project is so important because it is "major or
'revolutionary' impact", such a database will have great influence "on health care and
disease prevention.,,19 Knowledge of the 30,000 human genes will provide a vast
therapeutic repertoire with which the pharmaceutical industry can attack fundamental
aspects of human disease. Upon completion in 2001, the infrastructure of biology was
enriched, and the revolution of biology and clinical medicine accelerated.
The success of genetic manipulation may result in a better quality of life for people.
Some diseases may potentially be cured. As a result of genetic testing, risk prevention
and life style changes are possible. Or, if one knows of a recessive gene for a disease, it
will affect reproductive decisions. In a nutshell, the benefits of genetic manipulation
may be longer lives, less disease and perhaps "tailored" children.
It goes without saying that there are many ethical and religious arguments against gene
technology. Many people say that it will be an invasion of one's genetic privacy. Others
feel that genetic technology will have organizational problems. 20 For example, the
practice will be poorly regulated with the result that people can do as they please with
18 Included hundreds of scientists at 20 sequencing centers in China, France, Germany, Great Britain,
Japan and the United States.
19 K. Evelyn Fox, "Nature, Nurture, and the Human Genome Project"(1992), in Daniel J. Kevles and L.
Hood, eds., The Codes of Codes: Scientific and Social Issues in the Human Genome Project (London,
Cambridge: Harvard University Press, 1992) 281, at 294.
20 Darryl R. J. Macer, "Attitudes to Genetic Engineering" (1992), online: Eubios Ethics Institute
<www.biol.tsukuba.ac.jp. >
9developing genetic technologies.21 People also fear the fact that genetically engineering
humans will decrease the diversity of the human species, and make the human
population susceptible to diseases.22 This is a far-fetched notion, but a possibility
nonetheless.
Nevertheless, whether people like it or not, science does not stop. Like all new
technologies, genetic manipulation has its pros and cons. The potential for reward and
for disaster are both great. It is undoubted that with sufficient regulation and
responsibility, the benefits of genetic manipulation can far outweigh the drawbacks.
iii. The role ofbiotechnology in the modern economic development
The discovery of the structure of DNA in 1953 and the identification of DNA as the
genetic material in all life created a great leap in our understanding of life-forms from
bacteria to plants to humans. Armed with a better understanding of how organisms
"work," we are now able to engineer life to suit our needs through biotechnology.
Biotechnology is not an industry, but a set of biological techniques operating on living
organisms. As an area of science, biotechnology is often defined as a combination of
advances in our understanding of molecular and cellular biology, plant, animal and
human genetics. In short, Biotechnology is the integration of the natural sciences and
engineering to obtain the use of organisms, cells, parts of cells and molecular analogues
for products and services; Environmental biotechnology is the application of these
processes to the protection and restoration of environmental quality.
21 Ibid.
22 M. Millar, "Human Genetic Manipulation and Society" (1999), online: Technology and Culture
<http://www.loyala.edu/dept/philosophy/techne/gentech.htm.>
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Developed through decades of basic research, biotechnology is now being applied to
producing new, improved, safer, and less expensive products and processes used in
health care, food and agriculture, industrial processes and environmental cleanup,
among other applications.
Since the 1980s, biotechnology has been applied to commercially producing
diagnostics and therapeutics. Biotechnology companies thus were created specifically
to exploit the commercial potential of biotechnology. The biotechnology industry has
grown rapidly in recent years. The industry clearly makes substantial current economic
and fiscal contributions to the global economy.23
The United States has led the world in the commercial development of biotechnology
because of its strong research base-most notable in biomedical sciences-and the
ability of entrepreneurs to finance their ideas. During the early 1980s, a combination of
large-scale federal funding for basic biomedical research, hype surrounding commercial
potential, and readily available venture capital funding led to the creation of hundreds
of dedicated biotechnology companies (DBCs).
In 1988, the Office of Technology Assessment of U.S.A. verified that there were 403
DBCs in existence and over 70 major corporations with significant investments in
biotechnology.24 On Wall Street, biotechnology is recognized in some business reports
as a portfolio of stocks-in much the same manner as other technologies and industrial
sectors are so recognized.
23 Biotechnology Industry Organization (BIO), "Biotechnology Industry Statistics" (Spring 2002),
online: <http://www.bio.org.>
24 U.S. Congress Office of Technology Assessment, Biotechnology in the Global Economy (Washington:
U.S. Government Printing Office, 1991).
11
In 1999, over US$300 million was available through NllI for Small Business
Innovation Research Program (SBIR) grants. The biotechnology industry received
approximately 50 percent of these awards.25 As a sequel to the enormous investment,
American biotechnology companies obtained tremendous profits. Currently, there are
1,457 biotechnology companies in the United States, of which 342 are publicly held.
The total value of publicly traded biotech companies at market prices, was $224 billion
as of early May 2002.26 According to a recent report of BIO (Biotechnology Industry
Organization), prepared by Ernst & Young, the biotechnology industry has more than
tripled in size since 1992, with revenues increasing from US$8 billion in 1992 to US$
27.6 billion in 2001.
U.S. Biotech Revenues 1992-2001
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26 Biotechnology Industry Organization (BIO), "Biotechnology Industry Statistics". (December 2002),
online: < http//www.bio.org/ Biotechnology Industry Statistics. html>.
27 Ibid.,
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Based on the experience of the U.S. biotech industry, European companies are striving
to achieve significant benchmarks believed necessary for accomplishing sustainability,
including the ability to reach significant market valuations, develop a product focus,
gain access to technologies capable of producing multiple products, and develop a
complete pipeline.
The rate at which new companies are being created throughout Europe is astounding,
increasing by 173 in 2000 to 1,351. Germany, where the number of biotechnology
companies has risen more than 150 percent in the past three years, now claims the
largest number of European biotech companies. In Europe, industry revenues have
leapt forward over 2000, increasing by about 45 percent to 5.4 billion Euros. This is
approximately the level of U.S. industry seven or eight years ago, with a similar
number of companies.28
Canadian biotechnology first started some years after their American competitors, but
is proportionately comparable to the US field. According to the Figures of Statistics
Canada, in 1999 Canada's biotechnology sector generated C$1.9 billion in revenues
including C$718 million in exports (see the following figure). These revenues exceeded
C$5 billion in 2002. The total market capitalization of these firms was about C$ 12,9
billion by the end of May 1999. At the same time, the Canadian venture capital market
developed very rapidly in the last decade. In 1998, the total pool was estimated at C$
10 billion, and that year more than C$ 1.66 billion was invested in some 1200
companies, sixty of them active in biotechnology.29
28 Ernst & Young, "Convergence: Ernst & Young's Biotechnology Industry Report, Millennium Edition"
(2000]), online: Ernst & Young <http://www.ey.comlindustry/health>.at 68.
29 J. Niosi and Tomas G. Bas, "The Competencies of Regions Canada's Clusters in
Biotechnology"(1999), online: <http://www.wabio.comlindustry/econ_dev/CanadaClusterStudy.pdf>.
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84% of the $827M in R&D is done
within the health sector
• 70% of the Canadian companies are
in the health or agri-food sectors
• The health and agri-food sectors
represent 89% of Canadian
biotechnology revenues
• R&D represents 42% of the
revenues generated by this sector
• $1.9B in revenues and $718M in
exports
This industry has attached much attention In developing countries. In China, the
government believes that biotechnology will help to solve the most urgent problems,
such as in population, food supply, health care and environment protection. The
funding from government for R&D has been increasing continuously during the past
over 20 years. There are more than 400 universities, research institutes and companies
and a total of over 20,000 scientists and researchers involved in biotechnology. The
total sales of biotechnological products in China have increased by 50 times during the
past 10 years. In 1997, it was about 13 billion RMB (US$ 1.6 billion). In the year 2000,
it reached more than 20 billion RMB (US$2.5 billion). 31
30 Industry Canada. "Innovation Agenda and Biotechnology". (September 25, 2001), online: industry
canada <http://www.strategis.ic.gc.ca>.
31 Jin Ju. 2001, "Life Science and Biotechnology in China". (June 2001), on line: Chinagate <
http://www.chinagate.com.cnIDEVELOPMENTchinaGATEWAY.htm>.
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Biotechnology is likely to be seen as a national asset by more nations-both as a way to
develop a high-technology base and to increase market share in several international
industrial sectors. As commercial biotechnology expands in size and scope, its effect on
the international economy is obvious. Biotech companies raised more money in 2000
than they had in the previous six years combined. From 1994 through 1999, the biotech
sector raised a total of US$30.9 billion (excluding payments, fees and revenues from
partnerships). In 2000 alone, the sector raised almost US$31.4 billion on a global basis.
(See the following figure) 32
20.000
18.000
16.000
14,000
~
~ 12.000
iii 10,000
....
«i 8,000
'5
I- 6,000
4,000
2,000
o
Equity Investments In Biotechnology
2000
Total: $31,376M
Public Offerings
(Public Companies) Private Offerings
(Public Companies) Private Offerings
(Private Companies)
Of that, public offerings held nearly US$18.5 billion, equivalent to 59 percent of all
funds going into biotech companies. (See the following figure)33
32 J. V. Brunt. "A Superlative Year" (2001), online: Signals Magazine <http://www.signalsmag.com>.
33 Ibid.,
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Biotechnology is one of the world's fastest-growing industries, with global demand
expected to more that double from US $20 billion in 1995 to US $50 billion by 2005.34
Undoubtedly, the biotechnology industry is a key to global technological future, when
biotech companies obtain product approvals, growth can be dramatic, boosting job
levels and tax revenues. In the new 21st Century, the biotechnology industry holds
great promise to help the world meet its growing needs for innovative medicines, better
agricultural products and preservation of the environment. It is increasingly becoming
an important economic development strategy around the world as regions and
communities try to capture the economic benefits of this promising industry.
Encouraging and facilitating research will help bring these new technologies to fruition
and at the same time contribute to the economic development of global economies.
However, many biotechnology uses create legal issues, one of the most important
issues involving biotechnology and the law is the patenting of human genetic materials.
It is important that there be certainty in the law so that companies endeavoring to invest
large sum of money in research and development are secure in the knowledge that they
can protect their costly invention.
34 Canadian Biotechnology Advisory Committee. Patenting of higher hie forms and related issues:
Report to the Goverlllllent of Canada Biotechnology Ministerial Coordinating Committee. (Ottawa:
Canadian Biotechnology Advisory Committee, 2003) at 2.
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II. The Legal Status of Human Genetic Material
Owing to the tremendous potential benefits of biotechnology, the key to investment by
both the public and private in human genomics is the issue of intellectual property-in
particular, patent protection on biotech inventions. Some patents on biotech inventions
related to human genetic materials are hotly argued. The issue of patenting in this field
first appeared in 1991 when Graig Venter was identifying and sequencing hundreds of
small expressed genes in his research. Although the function of these expressed
sequence tags (ESTs) were not known, the Nlli decided to file patents on the ESTs.
Many scientists and patent attorneys were appalled at this preemptive claim on bits of
human genes, since their functions were unknown and it was presumed that these
applications would not meet the requirement for utility. 35
When the project to map the Human Genome Working Draft was made public on June
2000, debates around patenting of such material began. The issue has resulted in the
controversy in the legal world since it has touched the basic principle of the patent law,
in addition to moral and ethics issues.
Many Western countries have laws dealing with the donation of human organs and
tissue for purposes of transplantation and medical research, such as Canada and its
common law provincial Human Tissue Gift Acts.36 Generally, these laws are
35 J. V. Brunt, "Biotech Patent Fights"(October 2002), online: Signals Magazine
<http://www.signalsmag.com>.
36 Human Tissue Act, RSNB 1973, c. H-12; Human Tissue Gift Act, RSS 1978, c. H-15; Human Tissue
Gift Act, RSBC 1979, c. 187; Human Tissue Gift Act, RSA 1980, c. H-12; Human Tissue Gift Act,
RSYT 1986, c. 89; Human Tissue Act, RSM 1987, c. H180; Human Tissue Act, RSNWT 1988, c. H-6;
Human Tissue Act, RSNS 1989, c. 215; Human Tissue Act, RSN 1990, c. H-15; Human Tissue Gift Act,
RSO 1990, c. H20; and Human Tissue Donation Act, SPEI 1992, c.34. In Quebec, there is article 22 of
the Civil Code which states "A part of the body, whether an organ, tissue or other substance, removed
from a person as part of the care he receives may, with his consent or that of the person qualified to give
consent for him, be used for purpose of research." Furthermore, under the Civil Code, a person has the
right to decide what happens to his or her body after death. ( The note is continued on the next page.)
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ambiguous, however, with respect to genetic material, such as DNA, cells, and
derivative cell lines. These provincial laws successfully protect against the exploitation
and sale of organs, blood, etc., but do not address the ownership or possible patenting
of genetic material. Such material, as a biological entity, is unique and different from
other human tissues such as organs or blood. For this reason, the issue of patenting of
human genetic materials cannot be answered without having examined the status of
such material.
In general, genetic material is defined as a segment of DNA that codes for a protein.
The biological definition in terms of a stretch of DNA brings out both the physical and
informational aspects of genetic material: the stuff of DNA and the coded information
contained in DNA. Both the physical material itself and the information it contains
have immense research and therapeutic value, as well as economic and social
significance. However, the legal status of both the material and the genetic information
it contains, have not yet been settled in law.
i. Genetic Material
A gene is a sequence of DNA that constitutes the coded information for manufacture of
proteins and other key substances in cells. This genetic material is copied and passed on
between generations and copied to all cells of an organism. The substances produced
are responsible for the organization, development and maintenance of structure and life
possesses. Though genetic material is invisible to the naked eye, it has both a tangible
and intangible nature. Since almost all tangible things, other than human being, are
36 Continued ....
Article 43 of the C.c.Q. state "A person of full age or a minor fourteen years of age or over may, for
medical or scientific purposes, give his body or tissues therefrom." This act, however, is not designed
for human genetic materials.
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properties. Human genetic material could seemingly be considered as property.
However, genetic material emanates from, and is integral to the human being. It is
certainly for the law to regard such material as an extension of its human source, even if
it is not per se a human being. Then, what legal definition is used in practice?
Some cases have judged human genetic materials to be an object "sui generis". In Reet
v. Superior Court (Kane), the California Court of Appeal concluded that cryogenically
preserved sperm was a "unique" category of "property", which properly formed part of
a decedent's estate and over which the decedent had an interest in the "nature of
ownership". 37 Even if the sperm was not governed by the general law of personal
property, it occupied an "interim category" of "property" that was subject to the
jurisdiction of the Probate Court. 38 In contrast, the case of Davis v Davis, the Supreme
Court of Tennessee concluded that pre-embryos are neither person nor property and
entitled them to special respect because of their potential for human life.,,39
In Moore v. The Regents of the University of California, the majority of the California
Supreme Court refused to characterize Mr. Moore's interest in his surgically removed
spleen as sui generis. According to Justice Rothman of the California Court Appeal,
Mr. Moore's property right did not include the right to sell his spleen, even absent
legislation, which prohibits such a sale. Such interests could be described as "quasi-
property". This means that the object in question is in part property, but does not spawn
the whole array of property rights ordinarily associated with property.40 In other words,
37 M. Litman, "The Legal Status of Genetic Material. "In B. M. Knoppers, C. M. Laberge and M.
Hirtle, eds., Human DNA: Law and Policy (Kluwer Law International: The Hague/LondonIBoston, 1997)
17, at 26.
38 Hect v Superior Court (Kane), 20 Cal. Rptr. 2d 281-283. (Ct. App. 1993).
39 Davis v. Davis, 842 SW 588 (Tenn.1992)
40 Litman, supra note 37, at 26.
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such material is legally unique or sui generis. Accordingly, at some point in the
jurisprudential development of a sui generis right, it is appropriate to refer to it as
"quasi-property.,,41
Under classical civil law principles, the human body is outside of legal commerce.
Despite its material existence, the body is not considered a thing with pecuniary value.
Moreover, in accordance with general civil law principles and, more precisely, with
notions of morality and public order, the human body may neither be the object of
contract, not be sold, leased, or in any way alienated.42
In a 1991 opinion on the application of genetic tests to individual studies, family
studies, and population studies, the French National Ethical Consultative Committee for
the Life and Health Sciences took a firm position stating that an individual's genome
may not be the object of commercial transactions.43 It further affirmed this principle in
another opinion on the non-commercialization of human genome by asserting that "all
information contained in the human genome belongs to the common heritage of
mankind; it is a field of knowledge that cannot be subjected to monopoly.,,44 This
principle of non-commercialization of human body, its organs, tissues, cells and
products, was embodied in legislation in the French bioethics laws of 1994.45
Additionally, a report on the use of human tissue by the Health Council of the
Netherlands emphasized the right to self-determination over one's body, rejecting all
41 M. Litman and G. Robertson, "The Common Law Status of Genetic Material", in B. M. Knoppers, T.
Caulfield, and T. D. Kinsella, eds., Legal Rights and Human Genetic Material (Toronto: Emond
Montgomery Publications Limited, 1996)51, at 70.
42 M. Hirtle, "Civil Law and the Status of Human Genetic Material," in B. M. Knoppers, eds., Legal
Rights and Human Genetic Material (Toronto: Emond Montgomery Publications Limited, 1996) 36, at
85.
43 Ibid., 113.
44 Ibid., 113.
45 Ibid., 113.
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notions of property rights over the human body as a whole.46
These two European sources, largely influenced by similar civil law traditions, seem to
tend toward a "personality rights" basis for the legal regime for the human material.47
Several articles of the 1994 Civil Code of Quebec relevant to the disposal of body parts
or corpses are found under the title Certain Personality Rights and more specifically in
the chapter Integrity of the Person. This seems a clear indication of the legislator's
intention to opt for a personality rights approach to personal control over human genetic
material.
ii. Genetic Information
Genetic information is highly personal information. This information is encoded by
gene sequences that perform a variety of functions, most of which have not yet been
discerned. However, genetic information is qualitatively different from other types of
medical information, since not only is it highly personal but also it may impact
significantly on interpersonal, familial and social life.
Under the Common law, genetic information can be considered as either part of the
person or as property.48 However, the concept of ownership is very rarely used in
practice. Information tends to be protected by existing guidelines or through specific
legislation. The issue is, should it be protected in the same way or differently from
other medical information? In practice, most countries apply concepts of confidentiality
46 Health Council of the Netherlands, Committee on Human Tissue for Special Purposes, Proper use of
Human Tissue (The Hague: Health Council of the Netherlands, 1994) 32.
47 Hirtle, supra note 42, at 116.
48 B. M. Knoppers, "Status, Sale and Patenting of Human Genetic Material: an International
Survey"(May 1999) Nature Genetics 23, at 24.
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and privacy to genetic infonnation, but some want to give it special protection. In
Canada, the u.K. and to a much greater extent of U.S.A., there are some cases, which
regard genetic infonnation as confidential infonnation, namely, as property. These
cases suggested characterizing genetic infonnation as confidential infonnation
protected by relational wrongs such as breach of fiduciary duty and the law of infonned
consent, as well as the law of breach of confidence. The Supreme Court of Canada has
recognized that persons have privacy interests with regard to medical infonnation.49
China has classified "the human genetic resources and the relevant infonnation or data"
from an international scientific cooperation as "State scientific or technological
secrets".50 It considers genetic infonnation as property.
As concerns the patenting of human genetic material, one of the arguments centers on
the patenting of genetic infonnation, acquired through manipulation of genetic material
itself. Genetic infonnation is so private that some courts are unlikely to grant a broad
discretion to physicians to disclose genetic data to biological relatives or to
reproductive partners. The courts are even less likely to impose liability on physicians
and others for refusing to disclose this infonnation.51
Genetic material itself is truly unique because it has profound and far-reaching social,
psychological, scientific, and economic implications. These implications are best
regulated through the collective efforts of a variety of areas of law. Though the legal
49 McInerney v. MacDonald (1992), 93 D.L.R. (4th) 416. The Court held that a patient has a sufficient
property interest in the photocopy of documents prepared by other physicians to request an additional
photocopy from his or her physician without having to go back to the other physicians to obtain a
photocopy of the original.
50 See article 5 of the Chinese Interim Measure for the Administration of Human Genetic Resources,
1998. This Measure aims to prevent Chinese genetic resources from leaking. No articles relating to
human genetic materials were found in Chinese Civil Code.
51 Litman, supra note 37, at 27.
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status of genetic material is far from settled, case law will play an important role.
Legally characterizing this material as sui generis, as a prerequisite, should be an
appropriate legal rule to resolve this disputes on a case by case basic. In deed, as
concluded by Litman and Robertson concluded: rather than focusing on the legal
characterization of genetic material and information, and trying to assign to them
specific juridical categories such as property or person, courts should view them as
legally unique and use the flexibility of a sui generis approach to fashion whatever
rights, obligations, and remedies that policy demands in the particular context and
circumstances of each case.52 However, the sui generis approach, to some extent, is
ambiguous for patent law, because it creates a quasi property right but not complete
property. In this case, how could patent laws define the patentable requirements for
some sui generis "object"?
52 Litman, supra note 41, at 84.
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III. The Patenting of Human Genetic Material
In 1999, an article entitled "who owns our genes" in Time magazine stated: "in recent
years researchers have flooded the USPTO with application for thousands of genes and
gene fragments," the applications in fact are "a general idea of what specific strands of
genetic coding do, often it's just that-general..."s3 Much of the controversy surrounding
the patenting of genes stems from these applications. Who can or should own human
genes? Should it be considered as the common heritage of humankind at the level of the
genome or as a patentable subject matter at the level of individual genes? This enquiry
has created an ongoing and intense international debate.
Background
Since 1992, international bodies have repeatedly argued against granting patents on
naturally occurring DNAs, or cDNAs and ESTs of unproven utility or function. As
already mentioned, the controversy was sparked by the initial filing in June 1991 for
patent rights on 337 genes, and a second filing in February 1992 on 2,375 more genes
by Craig Venter. Venter's research at NIH's National Institute of Neurological
Disorders and Strokes aimed at locating and sequencing the 30,000 or so
complementary DNAs. cDNAs are clones made from messenger RNAs; thus, they
represent the coding regions of all the genes expressed in a tissue. By sequencing a
short stretch of eDNA clones, about 300 to 500 bases, Venter created ESTs. ESTs are
short sequences of DNA; they can be generated automatically by machines. Though
they are extremely useful in locating a full-length gene to predict the protein that gene
53 J. Kluger, "Who Owns Our Genes" (January 1999), TIME, at 35.
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makes, by their very nature, ESTs cannot disclose anything about their function. The
patent application for protection of this new knowledge has generated a number of
questions, some hotly debated. An USPTO ruling in 1992 denied the applications on
the grounds that gene fragments cannot be patented with an unknown function. 54
i. Controversies over the Patenting ofHuman Genes
Do ESTs, cDNA Sequencing and other early gene findings count as decisive
knowledge about the genes themselves? Venter was the first to admit that, even though
he could tag a cDNA, he still had no idea what it does, unless it is a sequence from a
gene whose function is already known. James D. Watson, who opposed this rush to
patent, decried this move. Members of the Gene Patent Working Group, an interagency
committee set up by the White House Office of Science and Technology Policy
(OSTP), meeting in May 1992, said that ESTs are merely research tools. 55 French
geneticist Daniel Cohen said there were two problems with the patenting of genes: "The
first is moral. You cannot patent something that belongs to everyone. It's like trying to
patent the stars. The second is economic. By patenting something without knowing its
use, you inhibit industry. This could be catastrophe." 56 So, the patenting of genes at
this stage was premature. Three years later following the first patent application on
ESTs, the NIH abandoned those original applications.
54 L. Roberts, "Rumours Fly Over Rejection of NIH Claim" (1992) 257 Science, at 1855.
55 T. Peters, "Intellectual Property and Human Dignity" in Mark S. Frankel and Albert H. Teich, eds.,
The Genetic Frontier: Ethics, Law and Policy (Washington: American Association for the Advancement
of Science, 1994) 215.
56 Ibid., 215.
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With respect to the issue of ESTs. Vast regions of the human genome lack genes and
harbor (only) highly repetitive sequences with questionable functions. In order to hunt
for DNA sequences that encode for proteins, researchers use ESTs. Obviously, an EST
can be used as a probe to identify the full-length gene of which it forms just a part.57
The hundreds of thousands of ESTs present in databases allow the search for other
ESTs whose sequences overlap and align them to give the nucleotide sequence of the
coding region or a substantial part of it.58
Even in Europe, where applicants also tried to obtain patents by providing just the
unspecific indication of an EST for use as a probe to obtain the remainder of the coding
region of the gene, they were not enough to fulfill the requirement of inventiveness
(and industrial application).59
Generally, there are important arguments against the granting of patent on human
genes.
Firstly, when examined critically, the claims made by industry for the benefits of the
patenting process are exaggerated. It is not true that patenting necessarily encourages
early and beneficial dissemination of knowledge which, without such protection, might
be kept secret. This is a widespread mythology about patenting, but in practice it is only
a half-truth. Patenting can indeed lead to the dissemination of information, but there is
also much information which remains secret. Many companies regard some things as
too sensitive even for patent protection, and some may be secret "in the national
interest". The high cost and lengthy timescale of seeking patent protection can often be
57 S. Huldebrand, "Patenting of Human Genes in Europe; Prerequisites and Consequences" (September,
2001), online: NDS Intellectual Property < http://www.ndsge.ethz.ch.>
58 Ibid.
59 In respect of art. 5 (3) and recital 24 of the Directive 98/44/EC.
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a deterrent for research institutes or small and medium enterprises, when compared
with a relatively short market advantage. Once a patent application is put into the hands
of patent lawyers, the questions asked - for example to widen the application of a
viable but narrow patent - inevitably divert a company's effort and personnel, which
may set back the company's ongoing research programs, and lose its competitive edge
in the next potential area of discovery. The litigation that can result from rival
companies claiming "prior art" can make patenting a doubtful and even more expensive
business.
Secondly, patents of partial and uncharacterized cDNA sequences will reward those
who make routine discoveries but penalize those who determine biological function or
application (inappropriate reward given to the easiest step in the process). Such patent
applications may also lead to so-called submarine patents, claims that are made today
and then vanish, only to reappear when some unsuspecting scientist finds something
useful to do with genes hidden in the patent.60 The patent applicants may seek a broad
scope of so as to prevent anyone else from developing and using them. On occasion,
patenting is abused by companies as a strategy deliberately to block a competitor from
developing potential products in a field which might rival an existing product, but have
no intention of ever bringing it to market. In such cases, public knowledge is reduced
by patenting.
And third, patents could impede the development of diagnostics and therapeutics by
third parties because of the costs associated with using patented research data. Patent
stacking (allowing a single genomic sequence to be patented in several ways such as an
EST, a gene, and a SNP) may also discourage product development because of high
60 Kluger, supra note 53, at 35.
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royalty costs owed to all patent owners of that sequence; these are costs that will likely
be passed on to the consumer.61 Costs increase not only for paying for patent licensing
but also for determining what patents apply and who has rights to downstream
products. In addition, because patent applications remain secret until granted,
companies may work on developing a product only to find that new patents have been
granted along the way, with unexpected licensing costs and possible infringement
penalties.62 It is also noted that private biotechnology sectors who own certain patents,
can monopolize certain gene test markets.
Finally, patenting human genes could be wrong because of public harmful
consequences. For example, it will enable patent holders to reap monopoly profits from
lifesaving therapies or diagnostic techniques. Patent holders are being allowed to patent
a part of nature --a basic constituent of life; this allows one organism to own all or part
of another organism. Ownership of life, or property rights in portions of human
. . h I 63genome, IS III erent y wrong.
ii. The Partisan Position
Some arguments in favor of patenting genetic material can be identified. The first was
stated by Philip Leder, the co-inventor of the Harvard mouse. In the course of the 1989
Congressional hearings on proposed U.S. legislation to restrict the patenting of
transgenic animals he stated: "The great and costly engine for invention can only be
effectively driven with the support from the private sector, motivated to serve a public
61 Oak Ridge National Laboratory, "Genetics and Patenting"(2001), online: Oak Ridge National
Laboratory <hup://www.omI.goy.>
62 Ibid.
63 Huldebrand, supra note 57.
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need. The patent system offers the only protection available for the intellectual product
of this research, and thus, the only hope of a fair return against the great financial risks
that investment in biotechnology entails.,,64
This argument can be interpreted as an appeal either to the inherent fairness of
compensation of those who take the risk, or to the assumption that patent protection
provides an incentive without which beneficial scientific and technological
development will be delayed. Dr. Leder argued that the Harvard mouse had great
potential for public benefit "as a vehicle for the development of further therapies" as
well as "an early warning system for the detection of carcinogens and mutagens" in
chemical testing. He pointed out that: "In the past few weeks, the gene for cystic
fibrosis has been identified and the ability to replace this gene, for example, in a mouse,
with the defective human cystic fibrosis gene would constitute an extremely powerful
model system for the development of an effective treatment. For individuals and
families at risk for this and other diseases, this would represent a priceless asset. ,,65
Similarly, Bernadine Healy, then Director of the NIH, argued during the 1992
Congressional hearings on the patent application policy of the Human Genome Project
that: "the success of Government-funded human genome research is of critical
importance to our Nation's public health" as the basis for "understanding the genetic
basis for health, disease, and life functions" as well as for developing therapies. "The
supportive and symbiotic relationship must be assured between emerging scientific
64 T. Schrecker, C. Elliott, C.Barry Hoffmaster, E.W.Keyserlingk, and M. A. Somerville, "Ethical Issues
Associated with the Patenting of Higher Life Forms" (May 17, 1997), online: Industry Canada <
http://www.strategis.ic.qc.ca/>.at 25.
65 Ibid., 26.
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developments and the intellectual property system.,,66 She went on stating: "[P]atent
protection for biotechnology and pharmaceutical industries is critical, bringing new
therapies to the public is a lengthy and expensive process. Not surprisingly, companies
are reluctant to invest the resources and take risks unless some market protection can be
obtained. ,,67
A second argument is based on considerations of economics. Patenting a gene does not
grant ownership of genetic information; on the contrary, it actually encourages the
publication and sharing of that information. It confers rights to the researcher to
commercially exploit that information, in defined ways, for a limited period. If there
were no protection of intellectual property rights, competitors could supply a beneficial
product at a much lower price, as they do now on the expiry of patents. This would
mean that industry would not invest in the research and development needed for new
medicines and diagnostics. Patent protection can establish a product's virtual monopoly
in the market place, one last long enough for the company to recoup the enormous of
cash that it poured into developing the product in the first place.
The third positive aspect is the consideration of fairness: people deserve the fruits of
their intellectual accomplishment. 68 Because biotech companies or research institutions
depend on private investments, patents are the first and most important benchmarks of
progress in developing a new biotechnology product. If such a patent is negated,
investments will be reduced and more participants will withdraw from the research.
Less and less competition will bring about the rising costs of products. Patents facilitate
transfer of technology to the private sector by providing exclusive rights to preserve the
66 Ibid., 26.
67 Ibid.,26.
68 Ibid., 27.
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profit incentives of innovating finns. Researchers are rewarded for their discoveries and
can use the monies gained from patenting to further their research. As Leon Kass wrote,
"justice requires protecting the labor of the imaginative and industrious against theft by
the sly and lazy".69 It should be noted that although the vocabulary is similar, there is a
difference between this argument and Philip Leder's invocation of the beneficial
consequences for society that can arise only if inventors and investors retain the "hope
of a fair return".
Finally, concerning the question that patenting of early gene findings would impede the
development of downstream products. Supporters argue that if further developing of
products is demanded by the society and is profitable, patentees, of course, would
develop it themselves. Even if patentees would not do it, others have the right to do it.
Since the patent law entitles one to use others' patent as long as it is done legally. 70 If
an improved technology is not subordinate to the early-patented product, it will not
constitute the infringement of patent. Furthennore, patents avoid wasteful duplication
of effort, as well as encourage research into new and unexplored areas.
69 L. Kass, Toward a More Natural Science: Biology and Human Affairs. (New York: The Free Press,
1985) 112, at 135.
70 See article 72 of the Chinese Patent Law, and art. 31 (b) of the Agreement on Trade-Related Aspects of
Intellectual Property (TRIPs), both of them regulate other use of the subject matter of a patent without
authorization of the right holder, including use by the government or third party authorized by the
government.
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IV. Requirements For the Patenting of Human Genetic Material
During the past thirty years, patent law has struggled to keep pace with the rapid a
growth of research and development in biotechnology. Not surprisingly, science has
outpaced the law, which is playing catch-up when it comes to providing patent
protection for biotech inventions involving genetic material. Difficulties remain over
the patenting of human genetic material under the traditional patent system. Much of
the controversy surrounding the patenting of genes stems from a misunderstanding of
the limitations of patent law. Numerous media sources often refer to "gene patents."
This term is imprecise and can lead to the belief that it is possible to file for a blanket
patent covering all the possible uses of a gene, or even a patent on the sequence itself.
For this reason, a review of patent law in general is necessary before discussing the
issue of patenting of human genetic materials.
Background
In each jurisdiction, patent rights are determined by reference to various national
statutes and to international treaties. Under patent law, a patent grants the patentee the
exclusive commercial proprietary right over a new, useful, and inventive creation. The
patentee may, for a limited period of time, prevent anyone else from making,
construction, emulating, using, or selling the patented invention, or any other invention
that achieves substantially the same result in substantially the same manner.71 In return
for granting a limited term of commercial exclusivity,72 the patentee must disclose his
71 T. Caulfield, K. Cherniawsky, and E. Nelson, "Patent Law and Human DNA: Current Pratice" in B.M.
Knoppers, T. Caulfield, and T. D. Kinsella, eds., Legal Rights and Human Genetic Material (Toronto:
Emond Montgomery Publications Limited, 1996) 117, at 119.
72 Canada's Patent Act, the Chinese Patent Law and the U.s. (The note is continued on next page)
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or her intellectual achievement. This enables others to replicate the invention for
experimental purposes and to freely use it once the term of exclusivity has expired. In
this way, patents are a dynamic compromise between undesirable market monopolies
and the broader social need for increased useful technological advancement.
Essentially, the rationale for a patent system is to provide an advantage to society as a
whole by rewarding the development of new inventions. Thus, the patent system has
two basic purposes: to promote the advancement of technology, and to protect the
inventor.
The legal threshold criteria of patentability and the rights encompassed in grant of
patent are quite similar in all jurisdictions. As a patentable subject matter, it must be
novel, inventive (non-obvious) and capable of industrial application (utility). Together
these three criteria ensure that only certain types of inventions can be protected and that
patent protection is commercially meaningful. The U.S. Patent Act § 101 defines
patentable subject matter or "inventions" as: any new and useful process, machine,
manufacture or composition of matter, or any new and useful improvement.73 Some
subject matters, by their very nature, cannot be patented, such as naturally occurring
organisms, laws of nature, natural or physical phenomena and abstract ideas. But, some
patentable inventions are excluded from the scope of patent protection based on public
policy. For instance, most countries, like China, Canada and the member states of the
European Union, prohibit the issuance of patents over plant and animal varieties, and
have adopted special laws to protect them. In addition, most national (not Canada) and
72 Continued..
Patent Act provide a 20-year protection period for a granted patent.
73 Canada's Patent Act, RSC 1985, c P-4, s.2., or Chinese Patent Law, 2001, art. 2, both have similar
definition of invention.
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international laws include a general prohibition against the patenting of illicit or
immoral inventions.74
The utility, novelty and inventiveness criteria are necessary before an invention is
classified as patentable subject matter. These three criteria are often difficult to achieve
when filing an application. Thus inconsistent case law has developed along side a
particular technology further compounding the problem of separating patentable from
non-patentable inventions on human genetic material. In essence, the debates focus on
whether a finding of a gene is an invention or a discovery; and whether it possesses an
industrial application.
i. Utility
Debates on discovery v. invention are closely related to the issue of the utility. Proof of
utility consists of two parts: an invention must possess industrial application and must
actually achieve the stated utility. This requirement guards against the granting of
undeserved or premature monopolies. A product that can be used as an intermediary
may not be adequate to establish legal utility, a useful end product or result must be
known. Moreover, the utility criterion distinguishes basic research from applied
research. The former has been traditionally considered as knowledge belonging to the
public domain that can be freely used, while the latter is regarded as an appropriate
subject matter for exclusivity.75 Although patenting of basic research would facilitate
the development of other subject matter into widely available commercial products,
74 Caulfield, Cherniawsky and Nelson, supra 71, at 122. See also article 5 of the Chinese Patent Law,
which "prohibits the issuance patents over subject matters with an illicit or immoral object".
75 Ibid., 132.
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such a practice might inhibit progress by discouraging the free exchange of materials
for fear that a competitor will invent around the protected subject matter.
A biotech invention involving human genetic materials must satisfy the utility
requirement by providing a clear application (such as a diagnostic test). But if the
invention contains a gene of unknown function, the invention does not possess the
requisite utility. Practically, the patent authorities in most nations accept that human
genetic materials and related processes fall within the sphere of patentable subject
matter and have applied tradition patent law maxims to these inventions. It should be
noticed that the technical character of the process of isolating a gene constitutes an
argument in support of the patentability only of the processes themselves, but not of the
elements that were isolated through these processes.
A typical case involving the patenting of human genetic material ESTs was the NIH
filed application in 1991 mentioned above. Although neither the structure nor the
functions of the ESTs were known, the NIH applied and pursued the patent application
to ensure that subsequent licensed innovators would be guaranteed adequate
commercial rights and the accompanying incentive to develop commercial products.
The NIH claimed that the ESTs satisfied the utility requirement since people could use
them for several purposes: to obtain full coding mosomes; to assist in forensic
identification; and to prepare items used in molecular biology such as vectors and
probes.76 However, opponents argued that the patent claim was overly inclusive and
that the premature issuance of a patent over such basic subject matter could secure
undeserved proprietary rights for the patentees, effectively transforming patents from a
system of rewards for the successful development of inventive commercial products
76 Ibid., 134.
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into institutions into a lottery based on luck.77 Ultimately, the USPTO denied the
claims for several reasons; one of them was lack of utility.
ii. Novelty
Novelty determines the scope of patent protection. Perhaps a difficult question for the
layman to understand is how a natural substance like a gene can have no previously
recognized existence since it is found in nature? The answer lies in the fact that a gene
is not necessarily part of the state of the art, which means accessible to the public in the
sense in which this term is used in patent law. To make a gene available to the public, it
needs to be isolated, purified, classified and identified from its natural surroundings.
The novelty arises now because the underlying technical processes for putting a gene -
preexisting in a complex mixture of natural origin - into practice requires human
intervention and cannot be accomplished by nature alone.78
Some who argued against granting patents on gene insist that genes and DNA are
natural parts of the body belonging to products of nature, and unsuitable for patent
protection.79 Products of nature are only discoveries that cannot be invented. Granting
patent protection over such discoveries improperly results in removing these pre-
existing human genetic materials from the public domain.8o However, if a new method
of production of a known product is discovered, then only the specific method can be
77 Ibid., 134.
78 See recital 21 of the Directive 98/44/ on the Legal Protection of Biotechnological Inventions, which
states: "Whereas such an element isolated from the human body or otherwise produced is not excluded
from patentability since it is, for example, the result of technical processes used to identify, purify and
classify it and to reproduce it outside the human body, techniques which human beings alone are capable
of putting into practice and which nature is incapable of accomplishing by itself."
79 M.S. Greenfield, "Recombinant DNA Technology: A Science Struggling with Patent Law" (May
1992) 44, Stanford Law Review 1075, at 1078.
80 Caulfield, supra note 71, at 136.
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protected. Thus, novelty is not a key barrier to the patenting of genetic invention, since
isolated and purified products are patentable if their new form is substantially different
from their natural form.
iii. Non-Obviousness / Inventiveness
The test of non-obviousness attempts to determine whether a person skilled in the
relevant art would have been inexorably led to the invention without research, on the
basis of common knowledge and other specified prior information.8! If publications in
the prior art collectively provide both the means to carry out the objective of the
particular invention, plus a reasonable expectation of success, then the invention is
obvious and not patentable. The following three factors should be considered when
determining whether the test of non-obviousness has been met: the scope and the
content of the prior art, the differences between the prior art and the invention, and the
level of ordinary skill of a worker in the art who lacks any imagination. 82
Inventions involving genetic materials, including the isolation and expression of DNA
sequences, are legally obvious if the prior art supplies a reasonable expectation of
success and thereby creates the motivation to produce the invention. Nevertheless, such
inventions will not be obvious if the prior art either offers no suggestions about which
of the experimental parameters are critical to achieving the desired result, or provides
only general guidelines in a promising area. Inventiveness may be derived from the
process used to achieve a result rather than the result itself. The requisite level of
81 R. W. Marusyk and A. I. Athanassiadis, "Patenting of Human Genetic Sequences In Canada", in B.
M. Knoppers, C. M. Laberge, and M. Hirtle, eds., Human DNA: Law and Policy (HagueILondon/Boston:
Kluwer Law 1997)343, at 347.
82 Caulfield, supra note 71, at 137.
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inventiveness may be reached if the materials essential to the invention are not
"available to the public" at the time of the invention.
In practice, it is very difficult to evaluate and determine the inventiveness of a claimed
invention in specific situations. That is why each patent office tends to examine the
inventiveness through the whole process of examination of patent application. Actually,
in the case of gene patenting, it is the very scope and quantity of claims that has
generated controversy. Since the initial patent on human genetic materials was issued.
Over 20 years ago, we have seen the courts continue to narrow the scope of biotech
patents on human genetic materials.
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v. Patentability of Human Genetic Material Under International Law
This chapter will analyze the legislation and recommendations adopted internationally
on the patenting of human genetic material. At the international level, the most relevant
texts are WTO's Agreement on the Trade Related Aspects of the Intellectual Property
Rights (TRIPs)83, and the Convention on Biological Diversity (CBD)84 adopted within
the framework of the United Nations system, as well as the Universal Declaration on
the Human Genome and Human Rights by UNESCO.85 At the regional level, Directive
98/44 on the legal protection of biotechnological inventions, adopted by the European
Union, is the only international instrument expressly regulating human genome
patenting.86
i. The World Intellectual Property Organization and the World Trade
Organization
The World Intellectual Property Organization (WIPO) is the specialized United Nation
agency responsible for the promotion of intellectual property worldwide. It administers
20 conventions and treaties in the field of intellectual property. Four key conventions
concern patents: the 1883 Paris Convention8? for the protection of intellectual property;
83 WTO's Agreement on the Trade Related Aspects of the Intellectual Property Rights, WTO, April 15
1994, online: WTO <http://www.wto.orglEnglish/tratop_e/trips_agmo_e.htm.>
84 Convention on Biological Diversity, U.N.T.S., June 5 1992, online:<www.biodiv.org.>
85 Universal Declaration on the Human Genome and Human Rights, U.NT.S., September 9 1998,
online: United Nations Education, Scientific and Cultural Organization< www.unesco.org.>
86 Division of Human Science, Philosophy and the Ethics of Science and Technology of UNESCO,
Intellectual Property in the Field of the Human Genome, SHS/HPE/2001lCONF-8-4/3, December 19,
2000, at 63.
87 Paris Convention For the Protection of Industrial Property, World Intellectual Property Organization,
March 201883, online: WIPO<www.wipo.int>
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the Patent Cooperation Treaty 88signed in Washington in 1970, 115 Member States by
the end of 2001; the Strasbourg Convention 89adopted in 24 March 1971, which
established the international patent classification; and the Budapest Treaty 900n the
international recognition of the deposit of microorganisms for the purpose of patent
procedure in 1977. In the past 30 years, with its unprecedented developments in the
field of biotechnology, these treaties may be too old to answer the questions
surrounding the patentability of human genetic material. The lack of protection and the
acts of "bio-piracy" denounced by holders of biological and genetic material both seem
to stem from inappropriate regulation. WIPO established its Global Intellectual
Property Issues Division (GIPID) in 1997, to deal with the challenges facing the
intellectual property system in a rapidly changing world.
The World Trade Organization (WTO) was established January 1, 1995, in Geneva.
The organization was formed through a series of talks between major economic
countries based on the Global Agreement on Tariffs and Trade (GATT).91 The WTO
provides a forum for negotiating trade agreements, handling trade disputes, and
monitoring national trade policies.92 The WTO appoints panels to assist in settling
trade disputes and in reaching agreements amongst Member States. The WTO adopted
the Trade Aspects of Intellectual Property Rights Agreements (TRIPs) in 1994. TRIPs
88 Patent Cooperation Treaty, World Intellectual Property Organization, June 19 1970, online: WIPO
http://www.wipo.int.
89 Strasbourg Agreement Concerning the International Patent Classification, World Intellectual Property
Organization, March 241971, online: http:// www.wipo.int.
90 Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes
of Patent Procedure, World Intellectual Property Organization, April 28 1977, online:
http://www.wipo.int.
91 General Agreement on Tariffs and Trade, October 30 1947, 58 V.N.T.S. 187, online:
http://www.wto.org.
92 See World Trade Organization, http://www.wto.org
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provisions are directly complementary to the international treaties administered by the
WIPO Secretariat. This Treaty is called the milestone of intellectual property because
of its exceptionally broad scope. This system has been described by the United Nation
Development Program (UNDP) as "introducing an enforceable global standard by
linking intellectual property rights with trade, making them binding and enforceable
through the WTO processes.',93
The scope of patentability under the TRIPs is quite broad. The only inventions that can
be excluded from patentability are those that are contrary to ordre public or to
morality.94 It does not exclude patentability of human genes, no more than it excludes
biomedical technologies such as cloning. Furthermore, there are no waivers for
chemicals or pharmaceutical products. This can have serious repercussions on the rights
to health and the rights of indigenous people. So far, the national laws of many
developing countries, such as China, Egypt or India have intentionally excluded drugs
from product patent protection (allowing only process patents) to promote local
manufacturing capacity for generic drugs and to make drugs available at lower prices.
The move from process to product patents introduced under the TRIPs dramatically
reduced the possibilities for local companies to produce cheaper versions of important
life-saving drugs, such as those for cancer and HIV/AIDS.
The TRIPs has caused controversies and is being revised. While the United States of
America has requested the elimination of waivers under article 27, developing countries
93 United Nations Development Program, Human Development Report, 2000, box 4.9. online:
http://www.undp.org/ reports/global/2000/en/pdf.
94 See art. 27 paragraph 2 of the TRIPs, which states: Members may exclude from patentability
inventions, the prevention within their territory of the commercial exploitation of which is necessary to
protect ordre public or morality.
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are seeking a broadening of exemptions concerning the patentability of living
organisms.95
ii. The Convention on Biological Diversity
The Convention on Biological Diversity (CBD) was adopted in 1992 in Rio de Janeiro
and came into effect in 1993. The CBD has three main goals: the conservation of
biological diversity, the sustainable use of its components, and the fair and equitable
sharing of the benefits from the use of genetic resources.96
Developing countries feel that the CBD enhances their control over their genetic
resources. Under the Convention, contracting parties have a sovereign right over their
genetic resources, but should endeavor to facilitate access to those genetic resources.97
The CBD states that where the genetic resources are the subject matter of patents, such
access is to be provided on terms which recognize and are consistent with the adequate
and effective protection of intellectual property rights. However, contracting parties are
obliged to ensure national patent rights are supportive and do not run counter to the
objectives of the CBD.98
However, the CBD does not clearly identify its material application scope: it contains
no specific reference to human genetic material, be it to include it or exclude it from its
scope. Indications may be derived from the definitions given under Article 2:
95 UNESCO, supra note 86, at 73.
96 H. Smith, "Challenge to the Biotechnology Directive," (March 2002) 24 European Intellectual
Property Review (London: Sweet & Maxwell Ltd.) 150, at 153.
97 Art. 3 and art. 15 of the CBD.
98 Art. 16 (2) and 16(5) acknowledged in recital 55 of the preamble of the CBD.
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Genetic material: means any material of plant, animal, microbial or other origin
containing functional units of heredity.
Biological resources: includes genetic resources, organisms or parts thereof,
populations, or any other biotic component of ecosystems with actual or potential use
or value for humanity.
Genetic resources: means genetic material of actual or potential value.
The Convention does not seem to rule out the patentability of human living organisms,
but its lack of specificity regarding the subject matter protected by intellectual property
rights, and its scope does not contribute to defining the perimeter of patentability
protected under the Convention. It should also be noticed that the CBD does not
establish whether genetic resources, including the human genome, can be subject to
rights of ownership. The CBD explicitly rejected the common heritage approach. It
favored the prerogative of individual, sovereign states. This offers a form of protection
for developing countries, but the legal status of human genetic resources remains
undefined. It clarified however in 1995 that "human" genetic resources were not
covered by the CBD.
In addition, under the Convention, individuals are dependent upon policy decisions
made by their states. Companies using intellectual property rights to gain control over
genetic resources such as sequences of human genome DNA would not be going
against any legal obligation arising from the CBD if the state where said resources were
located agreed to this and it was in agreement with international law (TRIPs, etc).
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Thus, the only rights actually mentioned and acknowledged are intellectual property
rights, which are to be provided with 'adequate and effective protection' .99 Although
the rule seems to provide for access to resources and the sharing of knowledge, with
intellectual property rights presented as an exception to this rule, (limited to those cases
where patents have been granted), intellectual property increasingly covers everything
related to plants, animals, and human beings. The exception shall no doubt soon
become the rule.
iii. UNESCO and HUGO
UNESCO
In line with its Constitution, UNESCO has long been engaged in standard setting in its
fields of competence, with the particular aim of maintaining, increasing and diffusing
knowledge with regard to human rights and fundamental freedoms. UNESCO is one of
the first international organizations to have attempted to frame bioethical principles for
genetics. The Universal Declaration on the Human Oenome and Human Rights of 1997
is a major achievement.
Since the initiation of the HOP, a group of scientists, ethics, attorneys and politicians
approached UNESCO and proposed a new international statement to the HOP. In 1993,
Mr. Mayor, the then Director-general of UNESCO, created the international Bioethics
Committee (rnC) to be responsible of the preparation of an international instrument on
99 CEAS Consultants (Wye) Ltd Center for European Agricultural Studies, Geoff Tansey, and Queen
Mary Intellectual Property Research Institute, "Study on the Relationship Between the Agreement on
TRIPs and Biodiversity Related Issues." Online: http://europe.eu.int/comm/trade/pdf/ceas_final.pdf:
Essentially, article 16 of the CBD preserves the entitlements of intellectual property owners as they are
defined in international law, such as TRIPs.
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the protection for the human genome. The IBC created a Legal Commission, chaired by
His Excellency Mr. Hector Gros Espiell. At its eighth meeting (November 1996), the
Legal Commission approved a Revised Preliminary Draft of a Universal Declaration on
the Human Genome and Human Rights. On November 1997, the General Conference
of UNESCO adopted the Declaration. The following year, the Declaration was
endorsed by the United Nations General Assembly and became the first international
normative instrument specifically on the human genome research. China has actively
supported and signed it.
The Declaration is composed of four major parts:
Human dignity and the human genome;
Principles for the human genome research;
Solidarity and international cooperation;
Promotion and implementation of the Declaration.
Article 1 states that the human genome is the 'heritage of humanity' in a "symbolic
sense". The idea is to emphasize the fact that research on the human genome and the
applications that may stem therefrom bring into play the responsibility of humanity as a
whole in the interests of present and future generations. The expression 'common
heritage of humanity' was subsequently changed to 'heritage of humanity', so as to
avoid any interpretation which would consider that human genome as possibly open to
collective appropriation, and a fortiori, to individual or private appropriation. IOO
100 UNESCO, supra note 86, at 76.
45
This obviously leads to ruling out patentability of the human genome at the level of the
species. Article 4 of the Declaration confirms this assertion, insofar as it states: "The
human genome in its natural state shall not rise to financial gains.,,101
Yet, at the level of the genes of individuals, UNESCO, in accordance with its calling to
further the sharing of knowledge, feels that the simple knowledge of human genes, or
partial gene sequences, in their natural state, cannot be subject matter to patent, and that
it must be freely accessible to all those involved in research worldwide. This does not
rule out the fact that research results on individual genes may be covered by intellectual
property rights. 102
As to the scientific cooperation, article 18 suggests that States should attempt "to
continue fostering the international dissemination of scientific knowledge concerning
the human genome, human diversity and genetic research ... particularly among
industrialized and developing countries". In general, the Declaration is not a binding
instrument, but to quote Mr. Mohammed Bedjaoui: [T]he formal adoption of a
Declaration on the protection of the human genome can only be the starting point for an
in-depth study, followed by effective practical measures worldwide to ensure that this
heritage is respected in all circumstances and transmitted intact to future generations. 103
HUGO
Even before UNESCO, the Human Genome Organization (HUGO) has been closely
watching patenting developments in the area of genomics and has analyzed its possible
impact specifically on further genome research. In 1997, after the decision of the
101 Ibid., 76.
102 Ibid., 76.
103 Ibid., 77.
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USPTa to grant patents on ESTs based on their utility as probes to identify specific
DNA sequences, HUGO urged the USPTa "to rescind these decisions and, pending
this, to strictly limit their claims to specified uses, since it would be untenable to make
all subsequent innovation in which EST Sequences would be involved in one way or
other dependent on such patents.,,104 On April 2000, HUGO issued the Statement on
Patenting of DNA sequences. In that statement HUGO emphasized that DNA
molecules and their sequences, be they full-length, genomic or eDNA, ESTs, SNPs or
even whole genomes of pathogenic organisms, if of unknown function or utility, in
principle, should be viewed as part of pre-competitive information. According to
HUGO, those ESTs without having found balanced solutions for the previous problem
of arising dependencies should not be patented, and SNPs should also remain
unpatentable. 105 Additionally, a mere DNA molecule and its sequence without
indication of a function does not contain any technical information and cannot
constitute an invention. Contrary to many critics of the E.U. Directive,106 HUGO
supports the Directive's regulation on such issues as patentable subject matter, specific
patentability requirements, scope of protection and ethical aspects of patenting in the
area of human genomics.
104 HUGO Intellectual Property Rights Committee, "HUGO Statement on Patenting ofDNA Sequences-
In Particular Response to the European Biotechnology Directive", April 2000, online:
HUGO<http://www.hugo_international.org>
105 The reason is that SNPs cannot be meet the requirement of inventiveness, also see HUGO statement
on Patenting of DNA Sequences.
106 For example, the Biotech Directive was unclear, in terms of when biotechnological inventions would
be ineligible for patent protection on ethical grounds; and historically could be seen to allow patents to be
obtained over isolated parts of the human body, which was offensive to human dignity from an ethical
point of view. See D. Curley and A. Sharples, "Patenting Biotechnology in Europe: The Ethical Debate
Moves on"(2002) 12, European Intellectual Property Review (London: Sweet & Maxwell Ltd.) 555, at
571.
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On the specific procedure to patent biotech invention involving human genetic
materials, the 2000 Statement on patenting of DNA sequences underscored that an
unambiguous indication and enabling disclosure of the function must be provided when
examining the requirement of industrial application of the claimed DNA molecules and
their sequences; and the patent offices and courts should "rigorously examine the
indication of functions or the function disclosed.,,107
Then in 2000, HUGO Ethics Committee published its Statement on Benefit-sharing. It
considered that the field of human genetics goes beyond the individual, the family, or
the population, a common shared interest in the genetic heritage of mankind. Therefore,
"we all share a common genetic heritage". 108
Although both UNESCO and HUGO have considered the human genome at the level of
the species as the heritage of humanity, how our genetic heritage is to be protected is
unclear. There is international consensus on the need to prohibit the more extreme
possibilities of human genetics. 109
107 See HUGO Statement on Patenting of DNA Sequences-In Particular Response to the European
Biotechnology Directive, April 2000.
108 HUGO Ethics Committee, "Statement on Benefit-Sharing", April 9 2000, online:
HUGO<http://www.hugo_intemational.org/hugolbenefit.html.> This common heritage approach is also
found in all of HUGO's Ethics Committee Statements since 1996.
109 B. M. Knoppers, Human Dignity and Genetic Heritage (Ottawa: Law Reform Commission of Canada
1991), at 74.
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vi. The European Patent Convention and The E. U. Directive
a. European Patent Convention
Patenting in Europe is governed by the European Patenting Convention (EPC) issued
on October 5, 1973, also known as the Munich Convention of 1973. This Convention
provides for a patent which is valid within 20 States (including 15 member States of
E.D.) and requested by the applicant in accordance with a unique and centralized
procedure which is carried out at the European Patent Office (EPa). In general, the
patentability of human genetic material had never raised any controversies in EPa
before the issue of patenting of ESTs. According to the article 52 of EPC, the invention
to be patentable must, 1) be an invention; 2) be novel; 3) present an inventive activity;
4) have an industrial application. However, those inventions whose commercial
exploitation could be "contrary" to morality or "ordre-public" can be opposed.
According to the EPC, there are product inventions; procedural inventions; and
inventions for the use of a product and for the use of an apparatus to initiate a
procedure. In these categories of inventions, product inventions have raised issues
around the patenting of human genes in Europe. The patentability of procedures and
methods is less criticized, such as--inventions for the use of a product or apparatus. no
But this does not mean that any procedural inventions dealing with human genes can be
patented. Rather, article 52(1) of EPC provides: "Methods of treatment of the human
body by surgery or therapy and diagnostic methods practiced on the human body shall
110 J. C. Galloux, "The Patentability of The Human Genome: A European Perspective" in B.M.
Knoppers, eds., Human DNA: Law and Policy (The HaguelLondonIBoston: Kluwer Law International)
361, at 363.
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not be regarded as inventions which are susceptible to an industrial application within
the meaning of (1)".
An invention may be carried out on living matter in European patent law. The EPC has
no provisions excluding such objects from the scope of patentability. As to human
genes themselves, in accordance with the article 52(2)a) of EPC, they are not patentable
because discovery by definition is not invention. However, the gene sequences are
regarded by the Opposition Division of the EPa as "a chemical substance carrying
genetic information, which substance may serve as an intermediary in the production of
proteins usable in the medical field".111 Further, as concerns the patentability of genetic
material "per se", one must patent not only the procedures for obtaining a product by
means of a genetic engineering method, but also the initial product and the result
achieved. That is, in so far as the product invention is concerned, one must have
identified and isolated the human genetic sequences.
Additionally, article 56 of the EPC stipulates that "an invention is considered as having
the attribute of an inventive activity if, for a person knowledgeable within the field, the
invention does not obviously follow form the state of the art". Since the rapid
development of knowledge and technique in the field of biotechnology, it is difficult to
anticipate the practical criteria for inventive activity in the field of DNA sequences. It is
likely that developments will be parallel to that within the field of chemistry. 112 For this
reason, the difficult isolation of a gene, the fact that it codes for an "inventive" protein,
the advantageous qualities which are as yet unknown or unanticipated when a gene is
III Ibid., 363.
112 Ibid., 365.
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inserted into a new organism: these are all means for determining an inventive activity.
Inventive activity is often confused with novelty.
Industrial application is also an important factor for determining an invention under the
EPC. Article 57 of the EPC provides that: "an invention is considered as having an
industrial application when its object may be manufactured or used in a some field of
industry, including agriculture." This provision poses certain problems in Europe. For
example, as to DNA sequences, the use as such of an intermediary product in obtaining
a final product fulfils the requirements for an industrial application. By contrast, the
mere use of a research tool yielding the possibility of an industrial application does not
appear to fulfill this condition. As a result, a claim applying for EST sequences without
indication about the function of the corresponding genes would not be considered as
having an industrial application. On the basis of the aforementioned objective
conditions for patentability, as of 1998, the EPa has granted 300 patents on genes
coding for human proteins out of 2,000 patent applications in biotechnology. 113
The Diplomatic Conference of the Revision of the EPC on November 2000 did not
address the patentability of biotechnological inventions. According to the States Parties
to the Convention, and in view of the current ED Directive on Biotechnology, and the
conformity of the EPC with its provisions, no further initiative is called for.
113Greenpeace, "Facts about the European Patent Office" May 1999, online: Greenpeace: <www.
greenpeace.org/reports>.
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b. The European Biotechnology Directive
A draft European Directive was first presented by the Commission in 1988. In the 10
years following, the European Parliament and the European Union Council as well as
the European Union Commission strived to harmonize this proposal for the Legal
Protection of Biotechnological Inventions. On May 12, 1998, the European Parliament
did vote in favour of the Directive for the Legal Protection of Biotechnological
Inventions, which had been adopted by the EU Council of Ministers earlier in the year.
The text was then formally accepted by the European Council, and published in the
Official Journal of the Communities on July 30, 1998.
The Directive had immediate effect on the way in which existing law on the legal
protection of biological invention was construed by the courts of the Member States.
Under article 15 of the Directive, member States had until July 30, 2000 to bring their
national patent law, regulations and administrative provisions into line with the
Directive. Although the Directive has no legally binding effect on the European Patent
Office, it was believed that the necessary amendments to, or an appropriate
interpretation of, the EPC enables it to comply with the provisions of the Directive.
The Directive is divided into five chapters, with each chapter dealing with separate
issues such as: Patentability; Scope of Protection; Compulsory Cross-Licensing;
Deposit, Access and Re-deposit of Biological Material. Contrary to much comment in
the press while the draft was going through the legislative process, the Directive did not
make major changes to the law of patentability in biotechnology. The most significant
feature of the Directive are the provisions pertaining to the patentability of biological
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material, including inventions relating to plant and animal varieties, the human body
and sequences or partial sequences of genes.
The Directive confirms that products consisting of, or containing, biological material
and processes producing or processes using, biological material are patentable if they
fulfill the requirements of novelty, inventive step and industrial application.1l4 Also
biological material isolated from a natural environment, or produced by a means of
technical process, is patentable, even if it previously occurred in nature. llS The human
body, at various stages of its development, including germ cells, is not patentable. This
includes a sequence or a partial sequence of a gene. An element isolated from the
human body or otherwise produced by a technical process, including a sequence or
partial sequence of a gene can be patentable, even if the structure of the sequence is
identical to the natural occurring form. Industrial applicability of the claimed sequence
must be disclosed in the patent application. 1l6
Patentability
As set out in Article 2, the Directive is dealing with "biological material" in general, i.e.
any material containing genetic information and capable of reproducing itself or of
being reproduced in a biological system. As further stipulated in Article 3&2, even
biological material which is isolated from its natural environment (and which is used
for whatever purpose) may be regarded as a patentable invention under the Directive.
Thus, the Directive placed emphasis on the distinction between discoveries and
114 Art. 3(1) of the Directive/98/44/EC.
115 Ibid., art. 3(2).
116 Ibid., art. 5.
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inventions. ll7 The fact that the biological material already occurs in nature does not
support the finding that it is allegedly a discovery. Further, the Directive relates to
microbiological processes 118 i.e. any process involving or performed upon or resulting
in microbiological material. Although the Directive contains no definition of a
microbiological material, one may infer that smaller constituents of biological systems
are contemplated, e.g. DNA, vectors, cells etc.
The human body and its elements
According to article 5, the human body and a simple discovery of one of its elements,
including the sequence or partial sequence of a gene, cannot constitute patentable
inventions. Thus, article 5 addresses two separate problems. Firstly, article 5 addresses
the issue as to whether the human body as such may be the subject matter of a patent.
The answer to this question is clearly no and as further stipulated in recital 20, any
rights conferred by a patent do not extend to the human body and its elements in their
natural environment.
As to DNA sequences, it was pointed out that a mere DNA sequence in the absence of
any indication as to its function is not a patentable invention. 119 Moreover, the
Directive explicitly requires that the industrial application of a sequence or a partial
sequence of a gene120 must be disclosed in the patent specification. As further
elaborated in recital 24, whenever a sequence or partial sequence of a gene is used to
117 Such distinction provided by Directive has been criticized for it eliminates the distinction between
discovery and invention in traditional patent law.
118 Ibid., article 2, paragraph 1 (b)
119 Ibid., recital 23.
120 Ibid., article (3).
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produce a protein or part of a protein, it is necessary to specify which protein or part of
a protein is produced, or which function it performs.
The other issue pointed out in article 5(1), relates to the distinction between inventions
and discoveries. Most importantly, article 5(2) of the Directive clarifies that an element
which is isolated from a human body or otherwise produced by means of a technical
process, including the sequence or partial sequence of a gene, may constitute a
patentable invention (i.e. the sequence has not been made available to the public before
the invention), even if the structure of that element is identical to that of a natural
element.
Ethical Issues and Morality
The Directive pointed out that a patent does not authorize the patentee to implement the
invention but merely entitles him to prohibit third parties from doing so. Thus, the
purpose of patent law cannot be to impose restrictions or prohibitions, notably from the
point of view of the requirements of public health, etc., or of compliance with certain
ethical standards. 121 Article 6 of Directive stipulates that inventions shall be considered
unpatentable if their commercial exploitation would be contrary to ordre public or
morality. In this regard, the following examples are given: 122
(a) Processes for cloning human beings,
(b) Processes for modifying the germ line genetic identity of human beings,
(c) Uses of human embryos for industrial or commercial purposes,
121 Ibid., recital 14.
122 Ibid., article 6 (2).
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Cd) Processes for modifying the genetic identity of animals which are likely to cause
them suffering without any substantial medical benefit to man or animal, and also
animals resulting from such processes.
Recitals 37 to 42 further elaborate on any such inventions that are contrary to ordre
public or morality. In this context it has to be noted that recital 42 clarifies that the
exclusion which concerns the use of human embryos does not affect inventions for
therapeutic or diagnostic purposes that are applied to the human embryo, and that may
be useful in that respect.
Deposit, access and re-deposit ofa biological material
Articles 13 and 14 of the Directive provide particulars on the depositing of biological
material. Such regulations have become necessary since there is no law concerning the
deposit of a biological material other than the EPC. The article 28 of the EPC, in its
new version, takes account of the provisions of the Directive.
In short, a legal framework has been created by the EPC and Directive in Europe for
applicants in the field of biotechnology. The Directive ensured that biotechnology
patent law is both strong and consistent across Europe, so that European consumers and
biotech companies are not disadvantaged with respect to their American and Japanese
counterparts. However, the Directive has been much criticized after its entry into force
by professional associations.
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c. The Criticisms of the Directive
The E.D. Directive has been much criticized for it does open the door to the patenting
of human genes. On October 19 1998, the Dutch government filed an opposition in the
European Court of Justice to the Directive, requesting the annulment of the Directive
under the Article 173 of the European Convention Treaty. The Dutch argued that it had
the wrong legal basis, as well as failing to respect the principles of human rights and
conflicting with international treaty obligations. This move was welcomed
predominantly by the Greens, who remain opposed to the patenting of biological
inventions and who were calling upon Belgium, Germany and Italy to join the action.
On July 6, 2000, the Netherlands further launched an application for interim measures
seeking the suspension of the Directive until the European Court of Justice had ruled on
the action for annulment.
In addition, UNESCO gave the most controversial points on the Directive in its report
of 2000. 123 They maintained that the distinction between discovery and invention in the
Directive is blurred, and that article 5 (2) contradicts the principles of patent law. It also
held that article 5(2) contradicts 5(1), since 5(2) considers genes to be inventions on the
sole grounds that they have been isolated or produced using a technical process, while
5(1) stipulates "human body, at the various stages of its formation and development
(... ) cannot constitute patentable inventions."
The UNESCO held that the Directive eliminates the distinction between a product
patent and a process patent. The Directive extends the effects of a process patent to a
123 UNESCO, supra note 86, at 80.
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product patent. It thus, confers to patents covering processes used to identify, purify,
classify or reproduce outside the human body (§ 21, preamble) the effects of product
patents. According to the Dutch, patents under the Directive not only cover the process
by which genes are isolated and reproduced, but also the gene itself and all its possible
uses: all in all they grant exclusive rights to produce, import and market the gene.
Finally, UNESCO also criticized the adoption of an approach that human beings are
reduced to an assembly of cells and DNA sequences. This commercial view of the
human body and its elements being regarded as spare parts offends the dignity of
human beings.
On the issue of disclosure of the industrial application of genes and the extension of
protection conferred, article 5(3) requires that the industrial application of a sequence or
a partial sequence of a gene be disclosed in the patent application. Requiring disclosure
of this type is not the same as requiring a demonstration through experimental
evidence. 124 In practice, function is simply deduced by companies on the basis of
computerized comparisons, and industrial function is then concretely presented,
whereas in actual fact it is only induced. By way of illustration, HGS patented the gene
CCR5.125 Years later, scientists discovered that this gene plays a crucial role in the
intracellular penetration of the mv virus. All therapeutic developments based on this
gene will however be dependent on the HGS patent, as the company may oppose the
use of the sequence, or require the payment of a fee. 126
124 Ibid., at 80.
125 HGS is Human Genome Science; CCR5 is a cell surface protein, now called an HIV co-receptor
essential for viral entry into cells.
126 Ibid., at 80.
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Whatever the pros and cons of the E.D. Directive, most of the Member States have now
grasped the nettle of implementation of the Directive, and are incorporating its
provisions into national patent law. While in the regulation of the use of biotechnology,
ethics and morality, are not a matter of primary concern within the patent system, the
European Commission has learned, polices in this field need to be developed in a
responsible way, in harmony with ethical values and societal goals. With these values
and goals in mind, it is hoped that the debate in Europe can move on and the objectives
of the European Commission for the life sciences and biotechnology sector fulfilled.
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VI. Patentability of Human Genetic Material under Comparative Law
This sixth chapter focuses on outlining the legal framework in U.S.A., Europe and
Canada, as well as China as concerns the patenting of biotech inventions derived from
human sources. This section begins with the U.S. patent system. Chief Justice of the
Supreme Court warren Earl Burger set the stage 20 years ago when he ruled
"everything under the sun made by man,,127 was patentable, the patentability of living
organisms has been non-stop. Companies and intellectual property lawyers have been
trying to pin down just exactly under what circumstances they could obtain an
unassailable patent on a biotech invention. Following a discussion of the American
requirements for the patenting of genes, comes an examination of current European,
Canadian and Chinese laws. A comparison will be made on the objective conditions for
obtaining a patent among these different countries.
i. The United States ofAmerica
In the United States of America invention patentability is determined by the United
States Patent and Trademark Office (USPTO), within the Department of Commerce, in
accordance with relevant regulations. Patents are regulated by US Code Title 35, last
amended in 1999 by the American Inventors Protection Act. America's legislation on
patenting of biotechnology inventions is the most advanced in the world, and its biotech
patent cases have also had a far-reaching influence on other jurisdictions.
The U.S. Patent Act, § 101 defines patentable subject matter as "any new and useful
process, machine, manufacture, or composition of matter, or any new and useful
127 See Diamond v. Chakrabarty, 447 U.S. 303,206 U.S.P.Q. 193 (1980)
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improvements thereof.,,128 Until quite recently, this Act was interpreted by the U.S.
Courts as excluding living organisms such as plants or bacteria, as well as human
genetic materials. For example, in the 1948 case of Funk Brothers Seed Co. v. Kalo
Inoculant CO.,129 the U.S. Supreme Court ruled that a patent could not be held on a
mixed culture of bacterial used for inoculating plant roots. Even though the patentee
had isolated the bacterial so that they could be more easily used in agriculture, he had
not created any new bacteria. Since the bacteria were a "phenomenon of nature," "part
of the storehouse of knowledge of all men," and not a new invention, they were not
patentable.
This interpretation of the Patent Act changed dramatically in 1980 in the case of
Diamond v. Chakrabarty.130 This is a starting point for addressing the interface
between biotechnology and patent law. In this case, the U.S. Supreme Court held that
an oil-slick-swilling, man-made microorganism is patentable. A patent was issued on a
genetically engineered living microorganism (it had naturally occurring bacterial
plasmids introduced into it) that was designed to digest and break down crude oil. The
patent was initially rejected by the patent examiner on the grounds that bacterial were
products of nature and non-patentable. The Supreme Court, however, cited records
accompanying the Patent Act of 1952 and said that " ...Congress intended statutory
subject matter to include anything under the sun that is made by man." According to the
Court, judged in this light, Chakrabarty's microorganism could qualify for patent
protection. Even though it had been derived in part from naturally occurring material,
128 35 U.S.C. §101,1988.
129Funk Brothers Seed Co. v. Kala Inoculant CO., 333 U.S. 127, 1948.
130 Supra note 127.
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the crucial difference between Funk Brothers and Chakrabarty was that in the first
case, the patentee had not altered the function of the bacteria, whereas in Chakrabarty,
a new bacterium (and thus a new invention) had been created.
The impact of Chakrabarty has been profound, since it opened the doors to a flood of
patent claims on plants, animals, and human genetic materials. 'Products of nature' are
no longer barred from patenting so long as the item in question is new, useful, and non-
obvious. For example, a human DNA sequence incorporated into a recombinant
bacterial host cell could be the subject of patents, as neither the recombinant DNA nor
the modified host cell occur in nature. It might even be possible to argue that purifying
and identifying a certain DNA sequence allows for patent claims as the new
recombinant DNA is an extract from DNA in its 'impure' form in the chromosomes.
In 1988, the Patent Office granted Harvard University a patent for a transgenic cancer
mouse (U.SA,736,866). This is the first patent on a living animal, also know as the
Harvard Onco-Mouse. This announcement marked a tum point in the debate about the
patenting of living organisms.
In 1997, the Clinton Administration announced that the PTO would begin allowing
patents on ESTs based on their utility as probes. Yet, faced with the increasing
contradictions between the patent law and the rapid development of biotechnology, on
December 21, 1999, the USPTO published a revised set of guidelines for the written
description requirement. Revised Interim Guidelines for Examination of Patent
Applications Under the 35 U.S.C. Section 112, 1, "Written Description" Requirement,
64 Fed. Reg. 71427, supersede the 1995 Utility Guidelines. Under the Revised Interim
Guidelines, the emphasis is on whether the utility of an invention is credible, specific
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and substantial. In addition, "throw-away" utilities, such as the use of a complex
invention as landfill, have been distinguished as nonspecific and insubstantial utilities
and therefore do not satisfy the utility requirement. Now, specificity and substantiality
of an asserted utility have been incorporated into the utility analysis to address concerns
regarding the patentability of ESTs.
Patentability
Under 35 U.S.C.101, an invention must be "useful" to be patentable. This is commonly
referred to as the utility requirement in patent law. According to the Revised Interim
Guidelines, to satisfy the utility requirement, the invention must have a specific and
substantial utility that is credible. An application can comply with the utility
requirement if the invention has any well-established utility. In addition, 35 U.S.C. 101
states that the specification should contain enough information to enable one to make
and use the inventions. There is a close relationship between the utility requirement of
section 101 and the enabling disclosure requirement of section 112. Indeed, in 1966, the
Supreme Court defined the standard for utility as a "specific benefit in currently
available form.,,131 The Court of Appeals of the Federal Circuit and its predecessor
court, the Court of Customs and Patent Appeals, have interpreted this as a minimal
requirement of practical utility. All that is needed is some form of real-world value or
practical utility.132 Thus, nearly any use for an invention should satisfy section 101 as
131 Brenner v. Manson, 383 U.S.519, 534-35, 148 U.S.P.Q. 689,685 (1966).
132 Nelson v. Bowler, 626 F.2d 853,856,206 U.S.P.Q. 881,883 (C.c.P.A. 1980).
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long as it is credible and does not violate a law of nature, such as the laws of
thermodynamics. 133
According to the Court, the essential criterion of novelty and non-obviousness
establishing invention patentability is the proof of "human intervention" or
"manufacture" (in section 101) on the matter to be patented, be it living or inanimate.
The USPTO interpreted the Court ruling in Diamond v. Chakrabarty that the Court did
not want to limit its ruling to genetically modified living organisms and opted for a very
broad interpretation of the term 'manufacture'. The Court in Diamond defined a
number of elements in order to test patentability under section 101:
laws of natures, physical phenomena and abstract ideas are not
patentable,
compositions of manufactures which do not occur in nature, are the
products of human ingenuity, and have a name, a character and specific
use are patentable,
the development of useable products using raw materials prepared in
such a manner as to give them new shapes, qualities, properties or
combinations, be it by hand, or by machines is a 'manufacture' under
section 101.
133 See, e.g. Newman v. Quigg, 877 F. 2d 1575, 1581,11 U.S.P.Q. 2d 1340, 1345 (Fed. Cir. 1989); see
also, Juicy Whip, Inc. v. Orange Band Inc. et aI, 185 F. 3d 1364 (Fed. Cir. 1999) (where an invention
designed to deceive customers by imitating another product in order to increase sales satisfied the utility
requirement) .
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As to human tissue and genes, the ruling handed down by the Patents Appeals Board on
April 21 1987 (1077 OG 24) maintains that human beings cannot be patented under
section 101, because such patenting would be unconstitutional. But, elements isolated
from human bodies, including organs, genes, DNA sequences as well as other elements
can be patented.
As to ESTs and SNPs, under the new Utility Examination Guideline of the USPTO, if
an isolated DNA fragment has a credible, specific and substantial utility, the DNA
fragment invention satisfies the requirement of utility and a patent can be granted for
such a DNA fragment. Where a new use is discovered for the patented DNA fragment,
that new use may qualify for its own process patent. Of course, the latter patent is a
dependent patent of the DNA fragment patent.
The first EST patent issued by the USPTO was US Patent No. 5,817,479 which was
issued to Incyte Pharmaceuticals, Inc. 134 This elicited q strong reaction on the part of a
number of scientists, who criticized what they felt was the excessive ease with which
the PTO granted patents, in this case on elements which could only be used as
instrument. Many commentators stated that sufficient patentable utility had not been
shown when the sole disclosed use of an EST was to identify other nucleic acids whose
utility was not known, and the function of the corresponding gene was not known.
Some commentators warned that such USPTO examination procedures would result in
granting patents based on non-specific and insubstantial utilities, contrary to established
case law, and so jeopardize the patenting of whole genes.
134 M. S. Tuscan and R. G. Adler, "Patenting of Expressed Sequence Tags in United States", (1999) 4 Bio
Science Law Review (Oxford: Lawtext Publishing Ltd.) 175, at 178.
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In general, the USPTO conferred very extensive protection on the patenting of genes,
with exceptions granted only for ' laws of nature, physical phenomena or abstract
ideas'. It should be noted that early U.S. patents on biotech inventions often included
seemingly broad, "prophetic," claims. During the past ten years, however, the courts
have gradually narrowed the scope of biotech patents. In Amgen Inc v. CJiugai
Pharmaceutical Co. Ltd. and Genetics Institute,135 the ruling prevented a company
from getting very broad-based claims on all DNA sequences that code for a protein or
analogs of that protein. Nevertheless, we will see that the USPTO's policy is still more
lenient with regard to the scope of patents and standards than other countries.
ii. Europe
In most European countries, although not all, patenting decisions are broadly governed
by the provisions of the European Patent Convention (EPC). Decisions about
patentability under the EPC are made by the European Patent Office (EPO). Since the
EPC was written before the advent of the recombinant DNA technology in 1973, the
EPO welcomed the reference point that the E.u. Directive provided by laying down
clear set of rules in 1998. The European Patent Organization amended the
Implementing Regulations of the EPC (which is an international Convention
independent of the European Union) by introducing new rules, taking effect from
September 1, 1999, to ensure that its interpretation is brought into line with the
provisions of the Directive.
135 Amgen Inc v. Chugai Pharmaceutical Co. Ltd. and Genetics Institute, 927 F. 2d 1200, 18 U.S.P.Q. 2d
1016 (Fed. Cir. 1991).
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In line with the American case of Chakrabarty, the EPO granted a patent for the first
microorganism in 1981. Within the same year, the company HOECHST AG applied -
presumably for the first time in Europe136 - for a patent (EP0034306) containing a
human gene. 137 The EPO conducted the same patentability analysis as for every patent
application and granted the patent in 1987.
On July 14th 1989, the Examining Division of the EPO, rejected in the first instance the
patenting of the Harvard Mouse. It invoked the principle that animal varieties could not
be patented, by way of application of Article 53b of the EPC. The applicant filed an
appeal. The Board of Appeal overturned the Decision of the Examining Division (OJ
EPO 1992, 58) and returned the application for further prosecution with the finding that
animals per se were not excluded from patentability by the EPC prohibition on the
patenting of animal varieties. As a result of that reassessment, the Examining Division
decided that the Harvard Mouse was patentable, at least partly on the basis that granting
the patent would not offend against the ethical exclusion in Article 53(a) of the EPC.
Before the Directive, the existing legal framework did not allow the patentability of
human genetic materials in the European Community countries. The Directive has
dramatically changed that approach and has led to the granting of a number of patents
on human genes. It ensures free circulation of patented biotechnological products
harmonizing the national legal system of each Member State, thereby guaranteeing
compliance with the EPC, the TRIPs and the Convention on Biological Diversity.
136 Christoph Then, "Gene, Monopole and Life Industry" (October 26 2002), online: Greenpeace
hUp:ll<www.greanpeace.org.>
137 It is Interferon.
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Exceptions to Patentability
Generally, excluded from patentability are inventions that are contrary to law and ordre
public or morality as well as processes for human cloning for reproductive purposes
and for modifying the germ-line genetic identity of human beings, as well as the use of
human embryos. 138
According to Article 53(a) EPC, no European patents may be granted for inventions
which are contrary to "ordre public" or "morality". Even though the EPC deals with
this Article in numerous cases, only the so-called PGS decision139 contains a definition
of the terms. Interestingly, the Directive addresses the question of "ordre public" and
"morality" in article 6140 and does provide a non-exhaustive list of the inventions that
are excluded from patentability. It does not define the terms however, article 27(2) of
TRIPS, on the other hand, explains in past which kind of prescriptions belong to "ordre
public" and "morality", including protection of life or health of humans, animals or
plants or to avoid serious prejudice to the environment. In summary, article 53(a) EPC
does not appear to be an extraordinarily restrictive patentability requirement. 141
Nevertheless, it is surprising that the EPO never considered it necessary to discuss
ethical considerations comprehensively with regard to claims on human genes. Only the
138 See article 53 of the EPC and article 6 of the E.U. Directive.
139 T356/93 Plant Genetic Systems, OJ EPO 1995, 545. It defined that inventions the exploitation of
which is not conformity with the conventionally accepted standards of conduct pertaining to the culture
inherent in European society and civilization are contrary to morality; the concept of the ordre public
encompasses also the protection of the environment.
140 See also article 23(d) of the Implementing Regulations to the EPC; By the way, the proposed
Directive's initial version stumbled over the issue of ethics and morals linked to the patenting of human
genes and human germ line therapy. In the final draft, the problem concerning patenting of human genes
was transferred to the level of the distinction between a discovery and an invention.
141 H. R. Jaenichen, The European Patent Office's Case Law On the Patentability of Biotechnological
Inventions (Koln: C. Heymanns, 1997), at 135.
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Relaxin decision142 deals with this issue stating that patents for DNA sequences do not
confer on their proprietor any rights whatever to individual human beings.
Furthermore, Article 54(4) states that methods for treatment of the human or animal
body by surgery or therapy and diagnostic methods practiced on the human or animal
body are not patentable. Conversely, "this provision shall not apply to products, in
particular substances or compositions, for use in any of these treatment."
Novelty
It is an established patent practice of the EP0143 to recognize novelty for a natural
substance which has been isolated for the first time and which had no previously
recognized existence. Article 5(2) of the Directive confirms this novelty concept of the
EPO by providing that "an isolated element from the human body or otherwise
produced by means of a technical process, including the sequence or partial sequence of
a gene, may constitute a patentable invention, even if the structure of that element is
identical to that of a natural element." Moreover, as reflected in the Relaxin decision,144
the claimed subject matter of a gene patent is often not genomic DNA but cDNA, a
totally artificial construct which does not occur in the human body. This supports the
admissibility of gene patents in consideration of the novelty requirement.
The question of the novelty of a partial sequence of a gene or a gene section including
the partial sequence can be answered positively, since the partial sequence of the
142 V08/94 Howard Florey Institute/ Relaxin, OJ EPO 1995, 388.
143 Part C, Chapter IV.2.3, Guidelines for Examination in the EPO; this novelty concept was already
applied by the German Federal Patent Court in 1978. See Naturstoffe, GRUR 238 (1978); Menthonthiole,
GRUR 702 (1978);
144 Supra note 142.
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invention had not been disclosed in its specific fonn. I45 Neither for that matter is a
partial sequence of a gene novelty-destroying as against full-length gene sequences. In
addition, even small differences within a DNA sequence are sufficient to confer
novelty. 146 Therefore, it can be concluded that the EPa applies the continuously
practiced "photographic novelty,,147 approach for DNA sequences as well. 148
However, problems may arise from the wording of the claims. For example a claim of
the type: "DNA, comprising the sequence...." may include sequence variations of the
state of the art which could lead to an objection based on lack of novelty. 149 The EPa
considers that a DNA claimed in this way cannot posses an unlimited length but a
length which is still suitable for the desired purpose.I50 It goes without saying that an
application which uses such a language in the claims has to sufficiently disclose its
invention to enable necessary delimitations.
Inventive Step
The assessment of inventive step in the EPa is carried out mainly with the help of the
so-called "technical problem-and-solution" approach. I51 According to this analysis,
145 Andreas Oser, GRUR Int 648 (1998)
146 T886/91 Hepatitis B virus/ Biogen, not yet published in the OJ EPa; The Technical Board of Appeal
of the EPa held that "the argument propounded by Appellant V that, in view of the particular nature of
the field, small differences in a sequence are not sufficient to confer novelty cannot be accepted by the
Board as it is well known that even a change in one amino acid can dramatically change the properties of
a protein molecule."
147 Photographic means "extremely realistic and detailed".
148 The EPa has used this approach in T886/91 Hepatitis B virus/ Biogen; and in T296/93 HVB antigen
production! Biogen OJ EPa 627 (1995).
149 Supra note 145; This problem could arise in connection with an EST and a corresponding full-length
gene.
150 EPa, USPTO and Japanese Patent Office. "Trilateral Project 24.1: Report on Comparative Study on
Biotechnology Patent Practices", online: <http://www.european-patent-office.gov/tws/sr-3-bio.htm>
(2001). To the same result occurs with recital 25 of the Directive 98/44/EC.
151 The so-called "could-would" approach is another method used by the EPa to judge inventiveness. See
T2/83 OJ EPa 265 (1984), T7/ 86 OJ EPa 381 (1988) etc.
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inventiveness will heavily rely upon a technical effect that could not have been
predicted from the closest prior art. The first granted gene patents were based on a
cloning technique in which the protein was first identified, and the gene was found
through tracking backward from the protein to identify the responsible gene. Even
though the basic principle of the underlying cloning technique was in every gene patent
the same, inventiveness was shown by providing technical differencesI52 between the
approach actually taken by the patentee and the methods disclosed in the prior art.
Since genes can be isolated and sequenced routinely with high-speed techniques, the
technical contribution to the state of the art depends (in the most cases) not anymore on
how the expert could arrive at the claimed DNA, but rather what can be achieved by it.
In contrast to sequence analysis, the task of identifying a function is a matter of
tremendous complexity and requires specific experiments that are individually tailored
to the particular gene. I53 It is usually not obvious to try the combined teaching of prior
art documents with a reasonable expectation of success. Hence, the indication of a
common function of the claimed DNA sequence is an essential criterion for
inventiveness.
These new tendencies regarding patentability of gene sequences were also transposed
into the Directive. Recital 23, which should be taken into account when interpreting the
Articles of the Directive stipulates that a mere DNA sequence without indication of a
function does not contain any technical information and is therefore not a patentable
152 E.g special probes (length, mixture of oligonucleotides); different hybridization conditions; different
mRNA isolation methods, technical differences to overcome difficulties in cloning the gene etc.
153 These may range from searching for the intracellular location of the gene product, testing expressed
proteins for a variety of potential enzymatic functions, attempting to construct knockout mice, attempting
to identify human or animal disease states in which the gene is disrupted, or attempting to interfere with
the function of the gene though antisense, ribozyme, dsRNA or related technologies. See HUGO
Statement on the Patenting of DNA Sequences (1995)
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invention. The function of a DNA sequence is in the articles of the Directive is
dogmatically tied to the industrial applicability154 and not to the inventive step. In any
event, the relationship is particularly close, since as a rule the indication of the function
or effect of the gene sequence can be used to derive the useful application and hence
industrial use.
As regards the issue of the guidance provided by the Directive, the question remains
whether a gene patent application requires the indication of the real biological function
of the claimed gene. Finding the biological function of a gene which enables the
commercial production of a therapeutic protein is an achievement that deserves legal
protection. However, where no biological function in the body is known, a gene which
confers a "normal" allele155 for good health can mutate to cause disease. This allows its
use as a diagnostic probe to accomplish a technical result. This is for example true for
BRCA,156 a gene with unknown biological function but usable in diagnostic kits to
screen women susceptible of having breast cancer. However, this leads directly to
issues surrounding the patenting of human genes. Is the "usability" of this gene
enough to get a patent, in the absence of knowledge of what it does? The grant of the
European Patent (EP 699754) on BRCA1 157 in January 2001 indicates that the EPO
generally accepts patents which disclose genes that can be used as probes to diagnose
specific diseases as long as there are no other reasons for rejection. DNA that is useful
for diagnosis will enjoy (like every chemical compound product) patent protection. But
154 Art.5(3) with the support of Recital 24; Rule 23(3)(e) of Implementation Regulation to the EPC.
155 B. Alberts, Molecular Biology of the Cell (New York: Garland Science, 2002), at 44. Allele means
one of a set of alternative forms of a gene.
156 Breast Cancer I.
157 D. Bulter and S. Goodman, "French Researchers Take a Stand Against Cancer Gene Patent" Nature
(September 2001) 95, at 96.
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a subsequent discovery of the real biological function of the corresponding gene is
again open to protection for useful applications.
Industrial Application and Utility
The European industrial application requirement as defined in Art (57) EPC can hardly
be compared with its US counterpart--the requirement of utility under 35 USC §101.
American patent law understands utility to mean usefulness. By way of contrast,
Europe, the question whether something is usable involves - among other things - the
idea of solving a technical problem, a concept that is decisive for the assessment of
inventiveness.
Since 1998, however, the Directive makes it clear that the interpretation of industrial
application should also be based on the idea of usefulness. Therefore, Art. 5(3) of the
Directive attaches more importance to the industrial application requirement having as
a result the gradual approximation towards the utility requirement in US practice.
ESTs(Expressed Sequence Tags)and SNPs(Single Nucleotide Polymorphisms)
ESTs
The Directive makes it clear that ESTs can constitute patentable subject matter by the
introduction of explicit references in the Articles to "partial sequence of a gene". Also
addressing EST sequences is Art. 5(3) of the Directive which requires the disclosure of
an industrial application. In cases where the sequence or partial sequence is used to
produce a protein or part of it, the specification of protein structure or the function it
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perfonns is required in order to comply with the industrial application criterion.158
Presumably the word "used" is directed to the use which confers industrial
applicability. Thus, the wording of the Directive leaves open the possibility that, when
the use which confers industrial applicability is not the production of a protein or part
of a protein, specification of a protein structure or the function it perfonns is not
necessary.
Thus, it seems that the Directive does not exclude a DNA sequence for which no
biological function is given from being patented. Yet, Recital 23 of the Directive
requires the indication of a function for a DNA sequence to be regarded as contributing
to the state of the art. 159 Moreover, patenting of ESTs cannot be looked at in isolation
from the patentability of full- length genes. 160 ESTs can have - like full-length genes -
unexpected technical effects even though the structure or the function of the
corresponding partial protein is unknown. It is for example imaginable that a certain
EST can be used to diagnose a specific disease or that it can simplify the distinction of
two cancers. Although no EST patents have been granted in Europe so far, it can be
assumed that the EPO will accept such patents if they fulfill the rigorous requirements
(especially with regard to industrial application and inventive step) of European patent
law.
SNPs
In the future, knowledge of SNPs will alter all aspects of medicine. In contrast to ESTs
which by their nature encode for partial proteins, SNPs are in regulatory regions, in
158 Recital 24 of the Directive,
159 See also Chapter Inventive Step.
160 See also recital 22 of the Directive.
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promoters,161 rather than in coding regions of the genome. Thus, they can raise slightly
different issues of patent law. 162 In any event, to be regarded as a patentable invention
(besides all other patent law requirements), a SNP has to show a technical effect that
could not have been obviously derived from the closest prior art.
It is unclear how many SNP applications have been filed, but hundreds are believed to
be in the queue at the European patent office. Despite controversial, ongoing, public
discussions, some of them may stand a good chance of being awarded patents.
iii. Canada
Canada takes an intermediate stance on the patentability of human genetic material.
Neither human beings nor their organs are patentable, but products derived from the
human body, including cell lines, genes, and DNA sequences are patentable.
Biopharmaceutical products obtained via gene therapy are also patentable.
As a member of the WTO and WIPO, Canadian patent law is subject to the provisions
of TRIPs and WIPO's patent law treaty. Canada is also less sensitive than the United
States about prior publication and therefore the disclosure of partial sequences will not
necessarily defeat all subsequent patent rights in genetic material and genetic related
inventions. We have seen that the United States Supreme Court ruling that life forms
are patentable, has fuelled the growth of the biotech industry.
161 Nucleotide sequence in DNA to which RNA polymerase binds to begin transcription. See Alberts,
supra note 155, at 44.
162 The British Group of AIPPI, "Patentability Requirements and Scope of Protection of ESTs, SNPs and
Entire Genomes" (2000) 22 European Intellectual Property Review 39 (London: Sweet & Maxwell), at
42; For example a complex disease may arise from quantitative, rather than qualitative differences in
gene products resulting from a SNP in a promoter region.
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In Canada, there have only been a handful of judicial cases dealing with human genetic
materials. The Canadian Patent Office has been far less willing to grant patents on life
forms. Some Canadian industry representatives have stated that the patenting policies
of other nations such as United States, Japan and Europe have more impact on
Canadian industry than does Canada's own patenting policy, gives the relatively large
size of those systems of its trading partners. 163 Therefore, Canada should work to
harmonize patent law and patent procedures internationally so as to enable Canadian
industry to take advantage of patents worldwide.
A Canadian patent can only be granted under the Patent Act. It can be obtained for a
product covering genes and genetic materials, a process covering processes of
manufacturing having little connection to genetic materials or a method covering the
use of particular products for particular purposes.
Under the section 2 of Canada's Patent Act, "invention means any new and useful art,
process, machine, manufacture or composition of matter, or any new and useful
improvement in any art, process, machine, manufacture or composition of matter." A
patentable invention must be novel and useful. With regard to living matter, section
12.03.01 of the Manual of Patent Office Practice (MOPOP) provides that inventions for
new microbial life forms such as bacteria, yeast, moulds, fungi, actinomycetes, algae,
cell lines, viruses and protozoa may be patentable.164 Being patentable, such inventions
must fully satisfy Section 34(1) and all other requirements of the Patent Act. Moreover,
163 Canadian Biotechnology Advisor Committee, Patenting of Higher Life Forms (Ottawa: Canadian
Biotechnology Advisor Committee, June 2002), at 23.
164 R. W. Marusyk and A. Athanassiadis, "Patenting of Human Genetic Sequences in Canada", in
B.M.Knoppers, eds., Human DNA: Law and Policy (The HaguelLondon/Boston: Kluwer Law
International 1997) 343, at 346.
76
the Canadian Patent Office has expanded the scope of unpatentable subject matter upon
reflection of Canadian case law dealing with patentable subject matter. Their express
position as stated in the MOPOP reflects the Canadian Patent Office's interpretation of
the Patent Act and case law. 165 This position holds that: There is no outright
prohibition under statute case law, or in the policy practice of the Canadian Patent
Office that would restrict the patentability of human nucleotide sequences or suggesting
that such sequences are improper subject matter. 166
In the case of 'Harvard Mouse', the Commissioner of Patents rejected the patent
application at the beginning. On August 3, 2000, the Federal Court of Appeal
concluded that a patent ought to be granted on the Harvard mouse. The Court ruled that
the wording of Canada's Patent Act, as it currently stands, permits the patentability of
genetically altered non-human mammals for use in carcinogenicity studies. On October
2, 2000, the Attomey- General of Canada filed an application seeking leave to appeal
the decision to the Supreme Court of Canada. On May 21, 2002, the Supreme Court
held a hearing and finally allowed the appeal for the reason of that an animal (in
particular mammal) could not be considered to be a "composition of matter" or
"manufacture".167 Higher life forms are still unpatentable in Canada. However, facing
with the fact that states have worked diligently to harmonize their patent regime,168 the
Supreme Court of Canada's approach to this case sounds highly discordant note. The
more similar Canadian laws and regulations are to those of its major trading partners,
165 Ibid., 345.
166 Ibid., 346.
167 Harvard College v. Canada (Commissioner ofPatents), 2002 see 76.
168 A patent for the Harvard Onco-mouse was issued in jurisdictions that cover USA, Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, The Netherlands, Portugal,
Spain, Sweden and the United Kingdom. A similar patent has been issued in Japan and New Zealand.
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the better the prospects of the biotechnology sector in the Canadian economy are
believed to be. 169 Therefore, no matter what the Court decides, the Canadian
government should consider whether further action is required.
iv. Patenting ofHuman Genes in China
Article 25 of the Chinese Patent Law (CPL) of 1985 bans the patentability of
"medicines or substances derived from the chemical methods". Thus, "microorganisms
and genetic substance inventions, bio-product inventions and gene therapy" are not
patentable.
But, in 1993, China amended the CPL and deleted the above-mentioned provision and
provided that "microorganisms and genetic substance inventions, bio-product
inventions" can be patented. The protection on biotechnology inventions in China has
basically kept abreast of developed countries.
In 1994, China signed the Patent Cooperation Treaty and became a member state of the
Budapest Treaty on the International Recognition of the Deposit of Microorganisms for
the Purposes of Patent Procedure in 1995. This led inventors in the field of
biotechnology to obtain patents in China. China amended the CPL again on July 1st,
2001, which brought Chinese patent law closer to WTO requirements. While it did not
give gene findings (such as ESTs) patent rights, it strengthened the patent rights and
simplified the patent examination procedure, as well exerting an active influence over
the protection of biotechnological patent.
169 Canadian Biotechnology Advisory Committee, supra note 163, at 25.
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a. Examination standards for patent applications related to human genetic
materials
At present, the CPO examines the application for biotechnology inventions involving
human genetic material according to the following:
-The microorganisms and the genetic materials are considered as the subject matter of
patentability.
Although there is no specific rule concerning the patenting of microorganisms under
the CPL, Article 25 of the Implementing Regulations of CPL and sections 2 (10) of the
Examination Guidelines hold that microorganisms are the subject matter of
patentability. Microorganisms include actinomyces, bacterium, fungus and virus, as
well as animal and plant cell systems, particles, protozoons and algae. Genetic
materials, such as genes, DNA, RNA and chromosomes, can be patented like other
chemical substances.
Yet, according to Article 25 of CPL, those microorganisms and genetic materials that
exist in nature and are not produced by means of any technical processes cannot be
patented. Additionally, the isolated or cultured microorganisms or genetic materials
must be in accordance with another requirement-the person skilled in the art can
repeatedly make and use them according to the specification. Otherwise, failure to
satisfy the utility requirement means they are beyond the protection of patent law.
-Bio-products are patentable.
The amended CPL deleted the provision that "medicine and the substance derived from
the chemical methods cannot be patented". Thus, bio-products that include vaccines,
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antitoxic serums, toxoids and so on are patentable. Moreover, patent applications
should be examined in accordance with the relevant standard of chemical substance and
medicine set out in the CPL.
As to the new chemical substance obtained by means of microbiology, patent petition
must be defined in molecular formulas or structures, the nucleotide sequence of DNA,
or the functions and the parameters of the claimed invention; Furthermore, the patent
specification must specifically disclose function and at least one production method.
-Methods for surgery, therapy and diagnosis (including stem cell therapy) are
unpatentable.
Article 25 (3) of CPL provides that "methods for therapy and diagnosis" cannot be
patented. However, the Guide of Examination provides for certain exceptions that are
not be considered as methods of therapy and diagnosis. For example, some medicines
and medical appliances used for therapy and diagnosis, and methods for determining
physiological parameter, can obtain patent protection in China. In practice, the Chinese
Patent Office (CPO) has already granted the patent to "methods for ultrasonic flaw
detector of blood" in 1988.170
b. Utility and scope ofthe patents
Article 22 of the CPL provides that the invention must meet the criteria of "novelty,
creativity and utility". This is essential and the purpose is to avoid granting patents to
basic research. But, under the CPL, there is no strict demarcation line between
170 Zhang Qinggeng, "The Protection of Biotechnology in China". Beijing University Law Journal.
(2000) 11, online: CHINAGENE<http://www.chinagenenet.com>
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fundamental research and applied research. How to distinguish between the two forms
of research is sometimes ambiguous in practice. Although the CPL clearly defines in
article 22 that the utility means "can be manufactured, used and produce the active
effects". How can we assess if "the active effect" is feasible and credible? No rules,
articles or even policy suggestions are found in the current patent law of China.
The patent system is meant to promote technology and economic development. If we
were eager to grant the patents to those inventions that fail to meet the criterion of
industrial applicability (although it could promote some basic research, such as
determining the sequence of gene), it would hinder the development of the
biotechnology industry in the long run. However, if the government did not give the
appropriate protection, it would render ineffective the exploitation of genetic resources,
and so would not benefit the later stage of the development of industrialization of
biotechnology.
Article 26 (4) of CPL regulates that "the written description should comply with the
specification and describe the scope of patentability." In addition, article 56 provides
that the scope of patentability on the invention and the utility model should comply
with the written description. The specification and drawing can interpret the claimed
patent right. So, the key to the examination of patent applications is to accurately
control the scope of patentability on the claimed invention. Determining the scope of
claim relates to not only the applicant or patentee's benefits, but also to the direction
and the function of the whole patent system. In principle, in order to obtain a patent,
only a technological process with complete disclosure, and its application can be fully
supported by the specification. Other applications based on subjective assumptions or
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on computer calculations and without the experimentation proof of its functions and
utilities, will not be granted a patent.
In contrast to the broad patent scope of the U.S.A., China is extremely strict in its
examination of gene patent applications. Regarding the patent application involving
human genetic material in China, up to the end of 1999, the CPO had received 1,754
patent applications, of which 475 were Chinese applications, and 1,279 applications
were foreign applications, coming mainly from the United States, Japan, Germany and
Great Britain. l7l No patent has yet been approved. Only if the patent applications
possess certain utilities or functions proven by the scientific experiments, will patents
be granted.
c. Ownership ofbiotech patents in China andforeign cooperation
It is very important to determine who holds the ownership of patents derived from
Chinese and foreign scientific cooperation in the field of biotechnology. In 1997,
Chinese scholars begun to notice that foreign researchers making use of Chinese human
genome diversity led to serious intellectual property losses for China. In The media
reported it as "[A]larm at foreign companies draining China's gene pOOl".173 These
allegations triggered the emergence of Chinese genetic regulations in 1998.
On June 10, 1998, China promulgated the Interim Measure for the Administration of
Human Genetic Resources. Article 2 defines human genetic resources as genetic
171 Chinese Intellectual Property Office, "Patent Statistics" (2003), online: http://www.sipo.gov.cnl
172 E.g. Chinese geneticists at the November 1996 Chinese Academy of Sciences meeting at Beijing
warned that China faces a gene drain and even foreign theft of Chinese genetic resources by foreigners
who take advantage of incomplete Chinese regulations.
173 See a report from U.S. Embassy Beijing, "Alarm at U.S. Companies Draining China's Gene Pool",
(April 1997), online: http://www.usembassy-china.org.cnlEnglish/sandt/generev.htm
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material including human organs, tissues, cells, blood specimens, preparation of any
types or recombinant DNA constructs, which contain human genes or gene products as
well as the information related to such genetic material. Article 3 regulates that
whoever is involved in such activities with respect to human genetic material in China
must comply with this Measure. Moreover, the article provides that the Chinese
research institution shall have priority of access to information about the human genetic
resources within the territory of the China. The foreign collaborating institution or
individual cannot apply for patent rights or disclose such information without
permission. As to the patent rights in collaborative research between China and foreign
institutions, article 19 (1) regulates that" a patent shall be jointly applied for by both
parties and the consequent patent right shall be owned by both parties." Each party can
implement such patents separately in his own country in accordance with the contract.
Transfer of such a patent to a third party shall be carried out upon agreement of both
parties, and the benefits obtained shall be shared according to their respective
contribution. Therefore, in relation to ownership of patent in scientific cooperation
between China and foreign countries, it should be noted that:
1) The Chinese institution has the ownership of genetic resources, no one can
apply for the patent without its permission.
2) The patent shall be jointly applied for by both parties, and the patent rights shall
be jointly shared by both parties.
3) Each party can implement such a patent in their own counties, but cannot
transfer it to the third parties without authorization of the other party.
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However, this Measure to detennine the ownership of gene patents is in conflict with
other Chinese law. The Chinese Contract Law (CCL) stipulates that: "unless otherwise
agreed by the parties, the right to apply for patents on the invention/innovation resulting
from a cooperative development belongs to the parties therein jointly".174 The CCL is
applicable to all contracts including contracts with foreign countries. Obviously, under
the CCL, the ownership of patent can be autonomously detennined by the interested
persons. Only if the interested parties do not agree, would they jointly own the patent.
Therefore, according to the CCL, there are three possibilities in practice: 1) the Chinese
party owns the patent right; 2) the foreign party owns the patent right; or 3) both parties
jointly own it. But under the Measure, there is only one possibility-"jointly own the
patent".
It should be understood that China promulgated such special regulations on the
intellectual property involving human genetic materials to prevent foreign companies
from owning or controlling those genetic resources alone. However, there is a clear
defect in the Measure since it excepts the Chinese party from owning the patent right
alone.
174 Article 340 of the Chinese Contract Law, 2001.
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VII. A Comparative Study of American and Chinese Biotech Patents
In the past decade, the biotechnology invention patent protection system has been
established in different jurisdictions. As the original and the biggest patent registration
system for the patenting of genes, judicial practice in the USA undoubtedly has an
important theoretical and practical value for others. This section compares the
requirements for the patenting of human genetic materials in the USA and China.
i. The Utility Examination Guidelines ofthe USPTO
According to the 1995 version of the Utility Examination Guidelines, the USPTO uses
a two-prong test to determine utility: whether the described utility is credible and
specific to a particular purpose. USPTO has also published its new 'Utility Examination
Guidelines' in 1999. The Utility Guidelines are applicable to all areas of technology.
However, they are particularly relevant in areas of gene-related technologies. Under the
new utility guidelines, USPTO moves to a three-prong test for utility: whether the
utility of an invention is specific, credible and substantial. In addition, a well-
established utility of the invention is always acceptable and easily recognized.
Specific utility
Specific utility means a utility that is specific to the subject matter claimed. This
contrasts with a general utility that would be applicable to the broad class of the
invention. For example, a claim to a polynucleotide whose use is disclosed simply as a
"gene probe" or "chromosome marker" would not be considered to be specific in the
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absence of the disclosure of a specific DNA target. The use of a protein as an antigen is
not a specific utility as essentially all proteins are antigens.
Substantial utility
Substantial utility means a utility that defines a "real world" use. Utilities that require
or constitute carrying out further research to identify or reasonably confirm a "real
world" context of use are not substantial utilities. Both a therapeutic method of treating
a known or newly discovered disease and an assay method for identifying compounds
that themselves have a 'substantial utility' define a 'real world' context of use. Basic
research such as studying the properties of the claimed product itself or the mechanisms
in which the material is involved; a method of treating an unspecified disease or
condition; a method of assaying for or identifying a material that itself has no specific,
substantial and credible utility; a method of making a material that itself has no
specific, substantial and credible utility; and a claim to an intermediate product for use
in making a final product that has no specific, substantial and credible utility are not
"substantial utilities".
Note that 'throwaway' utilities do not meet the test for a specific or substantial utility.
For example, using transgenic mice as snake food is a utility that is neither specific (all
mice could function as snake food) nor substantial (using a mouse costing tens of
thousands of dollars to produce as snake food is not a 'real world' context of use).175
The criterion of substantial utility did not exist in the 1995 version of the Utility
Examination Guidelines. The purpose of adding the substantial utility in the new
Guidelines is to eliminate' 'throwaway" utility.
175 USPTO. "Revised Interim Utility Guidelines For Examination of Patent Applications Under 35
U.S.C. § 112 "Writing Description Requirement", 64 Fed. Reg. 71427 (December 21, 1999), online:
USPTO<www. uspto.org/web/offices/>.
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Credible utility
An assertion is credible unless
(a) the logic underlying the assertion is seriously flawed, or
(b) the facts on which the assertion is based are inconsistent with the logic underlying
the assertion.
Credibility of a utility is assessed from the standpoint of whether a person of ordinary
skill in the art would accept that the recited or disclosed invention is currently available
for such use according to the disclosure of the application and any other evidence of
record claimed by the applicant. For example, a perpetual motion machine has no
credible utility because no perpetual motion machines would be considered to be
currently available.
Well-established utility
An invention has a well-established utility if a person skilled in the art would
immediately appreciate why the invention is useful based on the characteristics of the
invention and whether the utility is specific, substantial, and credible. "Well-
established utility" does not encompass any 'throwaway' utility that one can dream up
for an invention or a non-specific utility that would apply to virtually every member of
a general class of materials.
ii. A Comparison of the utility of DNA fragment inventions in the U.S.A. and
China
In inventions involving DNA fragments, the utility of ESTs is a highly contentious
issue. There is no doubt that an EST can be used to obtain the corresponding full-length
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cDNA and the genomic sequence, and an EST can be used as a marker to map the
chromosomal region of the gene. 176 But a potential use or a use for the purpose of
experimental research is not a specific or substantial utility.
According to the new Utility Examination Guidelines, the view of USPTO now is that
an EST whose use is disclosed simply as a 'gene probe' or "chromosome marker"
would not be considered to have a specific utility. EST is a form of DNA fragment. It
satisfies the requirement of utility if a credible, specific and substantial utility of the
EST, for example use as a probe to diagnose a specific disease, is disclosed.
China
At present, there is no re-examination board decision or court decision relating to the
utility of biotechnology inventions involving human genetic materials. There is no
related provision on "utility" in the Examination Guidelines of the CPO. Currently, the
CPO is instituting relevant Guidelines. The CPO should use the experiences of the
USPTO for reference in the institution on utility of examination guidelines for gene-
related inventions.
iii. The novelty ofbiotech inventions in U.S.A. and China
In the field of biotechnological inventions, the issue of novelty is often combined with
the issue of subject matter. The "Product of Nature" doctrine creates an important
restriction in biotechnology, because biotechnology products and processes may be
derived from the duplication of compounds found in living organisms or produced by
176 Dr M. Grund and Dr V. Vossius, "Patentability of ESTs under the EPC"(1998) 3 Bio Science Law
Review (Oxford: Lawtext Publishing) 106, at 109.
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naturally occurring animals or plants.177 If it is accepted that modified micro-organisms
and isolated and purified DNA sequences are the result of human intervention and so
are patentable subject-matter, naturally, they are "new" in the sense of having no
previous existence in the state of the art.
The Novelty ofDNA Fragment
As noted above, ESTs, SNPs and partial gene sequences, once isolated and
characterized and made available to the public (in for example a publicly accessible
database, whether or not one needs to pay for access) form a part of the state of the art,
in the same way as any other chemical. ESTs, SNPs, partial gene sequences and full-
length gene sequences are different chemicals. One chemical is not novelty-destroying
as against a different chemical; in the same way, ESTs, SNPs, or partial gene sequences
forming a part of the state of the art are not novelty-destroying as against full-length
gene sequences. 178 Similarly, a full-length gene sequence is not novelty-destroying as
against a section of it, if appropriately claimed.
In the "Biotechnology Comparative Study on Biotechnology Patent Practices
Comparative Study Report,,179 of 2001 by the USPTO, EPO and Japan Patent Office
(JPO), there is a posited case. The prior art (X) is a structural gene encoding a
functional polypeptide, the whole sequence of which is disclosed. The claimed
invention (Y) is a partial DNA fragment of (X). Does the claimed invention (Y) have
novelty over the prior art (X)?
177 Courtney J. Miller, "Patent Law and Human Genomics" (1997) 26 The Capital University Law
Review(Oxford: Lawtext Publishing), at 911.
178 The British Group of AIPPI, supra note 158,at 41.
179 EPO, JPO, USPTO, supra note 150.
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The answer is: an invention that relates to this partial sequence is regarded as being
novel when it relates to a partial sequence while has not been disclosed in concrete
terms in publicly known literature. 180 It resembles a selection invention. It seems that
the DNA fragment is new based on the reason of selection invention. But the invention
selecting a DNA fragment from a full-length gene sequence is not a selection invention.
The DNA fragment is an isolated compound that is different from the full-length gene
compound. Because the DNA fragment and the full-length gene are different
compounds, the full-length gene sequence forming part of the state of the art is not
novelty-destroying to the DNA fragment. If an invention of a DNA fragment isolated
from a full-length gene sequence is considered a selection invention, the DNA fragment
invention will become a dependent invention of the full-length gene invention. The
DNA fragment invention is not a dependent invention of the full-length gene invention.
The two inventions are independent.
China
At present, there is no re-examination board decision or court decision relating to the
novelty of gene-related inventions. There is no related provision in the Examination
Guidelines of the CPO. But then, as in other countries, if the subject matter issue of a
DNA fragment, gene, transgenic plant or animal, and so on is solved subsequently, the
novelty issue related is solved.
Moreover, in China, the exception to lack of novelty can be applied to inventions which
are exhibited at an international exhibition sponsored or recognized by the Chinese
180 Ibid., see chapter 2.2 of novelty.
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Government, made public at a prescribed academic or technological meeting, and
disclosed by any person without the consent of the applicant before the date of filing. 181
Compared with the exception to lack of novelty in US patent law, the scope of the
exception to lack of novelty in Chinese patent law is very narrow. So it is more
important to take equivalence into account to determine novelty of invention. Then, in
order to reduce the possibility that the technical information disclosed by the applicant
forms a part of the state of the art in favor of the inventive step in assessing the
corresponding patent application, not only identical invention but also a substantially
identical invention can be applied to the exception to lack of novelty.
iv. Inventive step ofbiotech inventions in U.S.A. and China
In Re Bell182
Early DNA patent cases focused on the obviousness of the method used to isolate the
sequence rather than the obviousness of the sequence itself. In Re Bell, the Court of
Appeals for the Federal Circuit (CAFC) focused on the structure of a DNA sequence
rather than on the method used to obtain the sequence.
In Re Bell, the USPTO reasoned that once a portion of the amino acid sequence is
known, the method for isolating DNA sequences encoding a given protein is obvious:
simply prepare and utilize nucleotide probes based on the amino acid sequence to
isolate the full-length DNA. Thus, the entire nucleotide sequence of the gene would be
181 Article 24 (2) of the Chinese Patent Law.
182 In re Bell, 991 F.2d 781 782,26 U.S.P.Q. 2d 1529, 1531 (Fed. Cir. 1993).
91
prima facie obvious when the amino acid sequence for that gene could be found in the
prior art. The Court commented:
" [I]t may be true that, knowing the structure of the protein, one can use the genetic
code to hypothesize possible structures for the corresponding gene and that one
thus has the potential for obtaining that gene. However, because of the degeneracy
(redundancy) of the genetic code, there is a vast number of nucleotide sequences
that might code for a specific protein."
The Court cautioned that its view was 'not to say that a gene is never rendered obvious
when the amino acid sequence of its coded protein is known' but that was not the
situation in the case. The art in question suggested use of only a short probe and the
applicants apparently had to choose a longer probe in order to obtain the gene in
question and thus had taken a step contrary to the prior art teaching. Thus, what the
applicants had done was not obvious. 183
In Re DeueZl84
In this case, the CAFC stated that the existence of art disclosing a protein and a
technique that can be used to determine the DNA sequence coding for that protein does
not make obvious the specific claimed DNA sequence coding for that protein. Due to
the redundancy of the genetic code, the disclosure of a partial protein sequence does not
suggest a particular DNA sequence coding for the protein. The fact that one can
conceive a general process in advance for preparing an undefined compound does not
mean that a claimed specific compound was precisely envisioned and therefore
obvious. The CAFC did state however, that a different result might occur if the prior art
183 lain C. Baillie, J. Richards and J. Gord, " Biotechnology and United States Patent Practice", (July
1996), online: Ladas & Parry <http://www.ladas.com/patentslBiotechnologylBiotechnology.USA.html>
184 In re Deuel, 34 51F 3d 1552, 34 U.S.P.Q. 2d 1210 (Fed. Cir. 1995).
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disclosed a small and simple protein so that all DNA coding for that protein would be
obviouS. I85
The difference from the principle of assessing inventive step also exists in related
comparative studies on biotechnology patents. For example, there is a posited case in
the 'Biotechnology Comparative Study on Biotechnology Patent Practices Comparative
Study Report' of 2001. The prior art (X) is a structural gene encoding a functional
polypeptide, the whole sequence of which is disclosed. The claimed invention (Y) is a
partial DNA fragment of X. Does the claimed invention (Y) have inventive step over
the prior art (X)?
The USPTO suggests only an assessment of the entire state of the art as well as the
information contained in the specification. It does not give an answer as to whether the
claimed invention has inventive step or not, because the USPTO holds that patentability
shall not be negated by the manner in which the invention was made. It is crucial
whether there is a suggestion or incentive to create the claimed invention in the prior
art.
China
As with utility and novelty, at present, there is no re-examination board decision or
court decision relating to the inventive step of gene-related inventions. There is no
related provision in the Examination Guidelines of the CPO.
In 1993, the inventive step criteria in a re-examination board decision of the CPO
(No.327) were similar to the inventive step criteria of the Biotechnology Patent
Protection Act of United States in 1995. In that decision, the board held that a new
germ must be considered to assess the inventive step of a zymolysis process in which
185 Supra note 181.
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the specific germ is used. The new germ is one of the indispensable technical features
of the invention. If the new germ is neglected, the process is a conventional technology
in the field of microorganism zymolysis. However, because the claimed process
includes the use of the new specific germ that is screened out by the inventor and the
claimed process has an advantageous effect, the claimed process has an inventive step.
In practice, the CPO will probably keep and continue to improve the principle that was
established in that decision.
v. The enablement requirement ofAmerican patent law
Specification is the core of the patent application. The patent office requires that
inventors must provide a high level disclosure to support the utility requirement of the
claimed invention in order to enable any person skilled in the art to make and use it, in
return for the grant of a limited term of commercial exclusivity. So, the purpose of a
specification is to satisfy an important legal requirement. For this reason, the patent law
of many countries regulates that specification must be fully, clearly and concisely
explained in the claimed invention. This principle is also embodied in the article 29 of
the TRIPs.
The 35 U.S.c. Section 112, 1 contains three requirements for patentability: 1) written
description; 2) enablement or how to make and use the invention; 3) best mode.
Interestingly, it is the issues surrounding "written description" and "enablement" that
lie at the core of the landmark biotech patent cases in U.S.A. The inventor must
describe the invention, teach how to make and how to use it, and provide the best
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known way of practicing the invention. In other words, if a person skilled in the art
makes and uses the claimed invention based on undue experimentation, the
specification would not be considered as the enablement, since the Section 112
regulates that the claimed invention must enable a person skilled in the art to make and
use the invention without undue experimentation as broadly as it is claimed. However,
if the term of the specification is feasible, but still needs the necessary experimentation,
such specification is also enabling.
Under Section 112, determining what is the necessary experimentation is important in
practice. In re Wands,186 the Court set forth a number of factors to be considered when
determining whether the specification is sufficiently enabling:
1) the breadth of the claims;
2) the nature of the invention;
3) the state of the prior art;
4) the relative skill of those in the art;
5) the predictability or unpredictability of the art;
6) the amount of direction or guidance presented;
7) the presence or absence of working examples; and
8) the quantity of experimentation necessary.
In the early gene patent applications, these eight factors, to the extent, were ignored so
that the scope of gene patent was broad. But today the court trends to narrow the scope
of gene patents. Among these eight factors, the level of predictability in the art is the
most important for determining whether a specification meets the enablement standard.
186 In re Wands, 858 F.2d 731,737,8 u.S.P.Q.2d 1400, 1404 (Fed. CiT. 1988)
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Unlike inventions in the areas of mechanical devices or electrical circuitry, those in the
field of biotechnology are often considered as unpredictable because scientists cannot
predict what kind of chemical or physical reaction a simple chemical change may result
in. As a result, the requirement of predictability in the field of biotechnology is
different from that in other scientific areas, and the biotechnology patent claims
involving human genetic materials are more likely to be rejected or held invalid than
that to inventions in other scientific disciplines.
vi. The enablement requirement under American cases
In general, US Courts have adopted a strict attitude towards the examination standard
on biotechnology patent applications. The enablement of gene patents firstly appeared
in the ruling of Amgen Inc. v. Chugai Pharmaceutical Co. Ltd in 1991.187 In this case,
Amgen had sued Chugai and Genetic Institute for infringing a claim to a DNA
sequence "consisting essentially of a DNA sequence encoding human erythropoietin
(EPO)". But the Court judged that it was not enough to know how a compound of
unknown structure (in this case, the EPO gene) might be isolated in order to claim the
conception; instead, the invention must actually isolate that gene. The Court disagreed
that the enablement of the plaintiff's right should have been expanded to all EPO
analogues, because the specification only disclosed how to make "gene and a lot of
unknown analogues", but not the "EPO analogues". This ruling is a restriction on those
who attempt to obtain patent protection for all possible variations in a given DNA
sequence. Therefore, even if the inventor could know all possible variations in a given
187 Amgen Inc. v. Chugai Pharmaceutical Co. Ltd, 927 F.2d 1200, 18 U.S.P.Q. 2d 1016 (Fed. Cir.1991)
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DNA sequence, he still cannot assert the patent right to all analogues unless he could
completely disclose the variations and consequences when encoding the DNA.
The USPTO takes a similar stance. The federal court has confirmed the aforementioned
finding in the case of In re Vaeck in 1991.188 In this case, the USPTO rejected the
plaintiff's patent application for lacking of enablement. The claims covering gene
expression in the broad genus of cyanobacteria were not enabled by a disclosure
containing a working example of only a single species of cyanobacteria out of more
than 150 different genera of cyanobacteria. The field was unpredictable and
cyanobacteria had been poorly studied. It was unreasonable to claim the broad scope of
protection because of the narrow disclosure. Therefore, the Federal Court pointed out
that unpredictability must satisfy a high level of disclosure to support the enablement
requirement. Later, the Court reaffirmed the same standard in other cases. 189
Moreover, in In re Wright, the full-scale of the aforementioned eight factors was
applied. 190 In that case, the court held that the plaintiff's right claim was too broad to
cover all vaccines for AIDS viruses. In fact, no effective vaccines for AIDS virus were
produced after the invention. Therefore, the court concluded it was inappropriate to
grant a patent to such an invention without enablement.
To determine whether a patent with broad claims meets the enablement requirement or
not, there are six factors that must be considered by US Courts:
1) The quality of required experimentation to obtain a patent: In Enzo Biochem, Inc. v.
Calgene, Inc.,191 the Federal Court affirmed the district court's finding that the claims
188 In re Vaeck, 947 F. 2d 488, 20 u.S.P.Q.2d 1438 (Fed. Cir. 1991)
189 See fox example, In re Goodman, 11 F.3d 1046, 1052,29 U.S.P.Q. 2d 2010, 2015 (Fed. Cir.1993).
190 In re Wright, 999 F.2d 1557,27 u.S.P.Q.2d 1510 (Fed. Cir. 1993) .
191 Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362,52 U.S.P.Q. 2d 1129 (Fed. Cir. 1999).
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were invalid as not enabled because undue experimentation was necessary to practice
anti-sense technology in cells other than E. coli, a prokaryotic organism. Successful
anti-sense regulation of three genes in one prokaryote, E. coli, did not enable the broad
scope of the claims. The inventor had attempted and failed to practice anti-sense
technology in yeast or in E.coli using alternate genes. The specification could not
enable the person skilled in the art to use this patent without undue experimentation.
Therefore, such experimentation was not enablement under section 112 because it was
only a form of creative experimentation.
2) Whether the unclear specification will cause the undue experimentation: In
Genentech v. Novo Nordisk,192 the plaintiff pointed out in the specification that the
"human growth hormone (hGH) could be produced by the expression of cleavable
fusion protein, and the conjugate protein enzyme was probably the cleavable carrier.
Although the plaintiff described the cleavable fusion expression of making the hGH in
theory in the specification, the plaintiff's patent specification did not contain sufficient
details concerning the practice of the claimed method. It was the unclear specification
that made a person skilled in the art fail to practice the claimed invention without undue
experimentation.
3) Whether there is unpredictability in the art: In re Goodman,193 the Court held that
there was a great unpredictability in the expression of plant DNA recombinant.
Goodman's own articles showed a need for extensive experimentation to practice the
claimed method for just a few plants, not all plant cells as broadly claimed in the
application. As a result, there was unpredictability in such a method for a person skilled
192 Genentech v. Novo Nordisk , 108 F.3d 1046,29 U.S.P.Q. 2d 2010 (Fed. Cir. 1993).
193 In re Goodman, 11 F.3d 1046, 1052, 29 U.S.P.Q. 2d 2010, 2015 (Fed. Cir. 1993).
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in the art since he could not precisely provide the reasonable result and the variation to
public when carrying out the claimed invention.
4) Whether the disclosure of a specification leaves a technical blank which the person
skilled in the art will fail to fill up with his knowledge in carrying out the patent: In
Genetech., the plaintiff asserted that those skilled in the art of recombinant protein
expression and purification would have been able to use the cleavable fusion
expression to produce hGH without undue experimentation by using the teachings of
the specification along with methods and tools well known in the art. However, the
Court held that the mere theoretical interpretation did not meet the enablement
disclosure requirement. Also the inventor must precisely describe in detail how to make
hGH by using the cleavable fusion expression. The written description did not mean the
invention was enablement. If those skilled in the art could not fill up the potential and
undisclosed technical blank of the specification, it would not meet the requirement of
section 112 §1.
5) Whether the scope of the claimed invention is too broad: In Enzo Biochem, Inc. v.
Calgene, Inc., the claims covered a broad range containing any genetic material
organisms, capable of being expressed, such as bacteria, yeast, other cellular organisms
and even· virus. Although the specification provided the application of anti-sense
technology in regulating three genes in the prokaryote E.coli, the Court pointed out the
fact that despite limited disclosure, "the claims at issue are all extraordinary broad,
encompassing an infinite number of cell types".194 So, the Court excluded the idea of a
mere germ from constituting enabling disclosure. Again, the broad scope was the
reason that the court held the claimed invention invalid.
194 See supra note 191, at 14.
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6) Whether there is a lack of successful case to practice the patent: The Courts did
consider the real world value and practice of the patent both in Genetech and in Enzo.
Biochem. In the former case, the plaintiff had not put his patent into practice until 5
years later following the approval of the patent; in the latter the plaintiff did not have a
successful case at all because the inventor failed to use the anti-sense technology in
practice.
As biotechnology advances, it has become increasingly routine to probe a cDNA library
and clone a gene. As a result, there may be fewer decisions invalidating biotechnology
patents under current patent law in the future. It may be possible that the written
description requirement will be easier to satisfy in the future as the technology becomes
better understood and hence the level of skill and knowledge of one skilled in the art at
the time of filing is quite high. Under this circumstance, one should not rely too heavily
on patent laws but rather be on the lookout for new case law.
vii. The inspiration for the Chinese biotech patent legislation
The concept of the patentability of human genetic material has been gradually accepted
in China. However, this concept is not mentioned in the Chinese Revised Patent Law
which only emphasizes the strengthening of patent protection. Chinese legislators have
not made the relevant legislative changes. Neither have court decisions. Little research
has been accomplished by the Chinese legal academic experts on the patentability of
biotech inventions. So, using the US judicial experience and practice for reference is
significant for Chinese biotech legislation.
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Article 26 of the CPL and the article 18 of the Implementing Regulation of CPL
regulate the principle of the specification. In China, "complete disclosure" is the
essential requirement for the invention patent application. The standard of 'complete
disclosure' means that the specification should contain a full, clear, and concise
illustration, which would "enable a person skilled in the art to make and use the
invention without undue experimentation as broadly as it is claimed." This is similar to
the principle of "best mode" and "practice mode" under the US patent law for
determining enablement.
To a certain extent, Chinese patent law has established gene patent protection in
principle. In this case, the law should only provide some principles for the issue of the
patentability of genes, and the detailed operating rules might be regulated in "Guideline
for Examination of Patent Application, in which the article 26 of the CPL and the
article 18 of Implementing Regulation could be embodied in the field of patentability of
inventions involving human genetic material. 195 As to the detailed regulations, US
related judicial experience is obviously valuable to China. In consideration of the public
policy issue and conditions in China, the "balance of interests" principle also requires
that the written description should strengthen the disclosure.
Since the first patent on EST in 1980, globally gene patent applications have been
rising rapidly. Compared with patent applications of 1999, the growth rate was 6000%
195 Article 26 of the CPL stipulates that the description shall set forth the invention or utility models in a
manner sufficiently clear and complete; According to article 18 of the Implementing Regulation, the
description shall include technical field, background art, contents of the invention, description of figures,
and mode of carrying out the invention or utility model.
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by the year to 2000 (up to 3,773,224 gene patent applications).196 According to
statistics of the Chinese Intellectual Property Office, it was estimated that globally, the
USA owns 90% and Europe and Japan own 8% of total gene patent applications while
other countries share the rest, which is only 2%.197
As a developing country, the China scientific and technological level limits patent
applications involving human genetic material. They must be strictly examined in order
to prevent the board claims from injuring the development of related industry. As one
of three factors in the written description, the requirement of enablement should be
strengthened. For example, the Japan patent law is very strict with regards to the scope
of gene patents. The court interprets the patent application in a narrow sense, but the
principle of equity of the injunction 198 in patent-infringement lawsuits is strictly
limited in Japan. This policy gives Japan biotech industry a relatively large space when
applying for patents. The Japan biotech industry stands in an advantaged position in the
gene-war against its American opponent. Additionally, one of the purposes of the US
Utility Examination Guideline is to raise the examination standard and apply a stricter
approach to biotech patent applications.
196 Chinese Intellectual Property Office, supra note 167.
197 Ibid.,
198 See article 100 of the Japan Patent Law and the 35 U.S.C. 283, which regulate that the court having
jurisdiction of cases may grant injunction in accordance with the principle of equity to prevent the
violation of any right secured by patent.
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Conclusion
The patent paradigm has been irrevocably placed upon inventions involving human
genetic material. Developments in human genetics over the next 20 years and derivative
disputes will continue to be played out within the patent regime. The patent debate is an
evolutionary process in different stages of development in jurisdictions around the
world.
The different cultural, moral and legal concepts governmg each country causes
different judicial solutions to the issue of the patentability on human genetic materials.
While Canada struggles with the concept of the patentability of higher life forms,
Europe remains focused on the basic propriety of patents, and the US is attempting to
reconcile economic and industry realities within the confines of the traditional patent
system. Developing countries have been trying to protect their rich genetic resources
from the biopiracy actions of industrialized countries. Our discussion has illustrated
how difficult it is to create legal principles of general application which not only retain
the qualities of relevance and justice over time, but also harmonize rapid and often
unpredictable technological changes in addition to unique moral and social challenges.
During the past 20 years, patent protection of biotechnology inventions has gradually
developed and is regarded as the most appropriate way to protect genetic resources.
Human genetic material has been categorized within pre-existing subject matter classes.
DNA sequences are treated simply as any other complex chemical substance in both
national and international patent offices. Patents have been issued over human genes,
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human genetic material and other related inventions out of the Canada Patent Office,
the European Patent Office and the u.s. Patent Office, often without any special
consideration of their origin or social implications. Despite this seemingly established
pro-patent practice in the courts and patent offices, the patentability of such invention
involving human genetic material remains controversial. 199 Public policy arguments
have not been successfully employed to prevent the patenting of human genetic
material, but public concern over the ownership of human genetic material is real and is
arguably justified.zoo Maybe this concern will influence any modification of the current
patent system in the future.
In the patent law of most industrialized countries, the distinction between discovery and
invention is gradually being eliminated. The examination standard, however, has been
improved by courts and patent offices. As a sequel, the issue of the early so-called
"submarine patent applications" has been effectively limited. Companies and patent
lawyers cannot obtain the patent unless the claimed invention totally meets the
requirement of the three principles of patent law.
Meanwhile, developing countries have adopted the least favorable approach to the
patentability of human genetic materials because of the great economic gap between
them and industrialized countries. China, India and other developing countries with rich
human genetic resources worry about "biopiracy" from developed countries and that
the economic discrepancy between both parties will lead to inequitable exploitation of
199 Caulfield, supra note 71, at 146.
200 Ibid., 147.
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their genetic resources. They hope to adopt a form of protection which differs from the
intellectual property right's system, in that it is less exclusive, the pattern of
cooperation should be "benefit-sharing". Nevertheless, putting undue emphasis on the
protection of genetic resources by maintaining either that "the human genome is the
common heritage of humanity" or on "benefit-sharing", is not enough. Rather than
emphasizing mere protection, developing countries should further their patent law,
strengthen the examination standard and use the experience of industrialized countries
as a reference to protect their own invention in the domain of patent law.
The above comparative analysis of the patentability of human genetic materials and the
related judicial practice both in international and national jurisdiction leads to the
conclusion that it is necessary and feasible for China to adopt legal patent protection for
human genetic materials. On the one hand, the pressure of competition in
biotechnology industry forces China to grant patents on human genetic material as soon
as possible. If China insisted on retaining the old legal concept that human genetic
material is not patentable, and does not regulate any practical examination guideline on
it, Chinese biotechnology industry would face powerful challenges from their foreign
counterparts in the immediate future.
On the other hand, the Chinese patent legislation, in principle, has already opened the
door to the patenting on human genetic material. After the first amendment of the CPL
in 1993, the chemical substance was formally taken into the patent scope. Genetic
material, such as gene, DNA, RNA and chromosome, which belong to bio-chemical
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substances, can be patented like other chemical substances. Moreover, in addition to
provisions of the CPL related to microorganisms, American experience on the patenting
of human genes should be referred to by the CPO. Some statutory provisions and case
law must be considered when determining the patentability of a given "genetic
invention."
The following are recommendations for Chinese legislation on the patentability of
human genetic materials.
1. Some scholars suggest protecting the biotech invention by a special law that
differs from patent law. But in practice, only the new plant variety is protected
by the special law. Furthermore, some recent important statutes or case law on
biotech inventions, both in America and in Europe, are still within the scope of
patent law. In general, they adopt a way of combining promulgating the
individual act and adjusting the requirement of examination standards to deal
with the issue of the patentability of human genetic materials. Therefore, special
type protection could be used in the scope of the patent law in China. In short,
we advocate the return of patent protection to biotech inventions by way of
special legal protection.
2. The distinction between discovery and invention should be reduced; the
requirements of patentability on human genetic material should be improved;
and the principle that "if patent applications related to human genetic materials
meet the substantial requirement of patents, they can be granted the patent"
should be established in Chinese patent law. The Chinese legislator could
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consider human genetic material as an invention by referring to the regulations
of the CPL with respect to microorganisms. In that case, provisions of the E.U
Directive and U.S. patent law are also worth referring to.
3. In addition to the three criteria requirements of patent law, the CPO should
emphasize the effect of gene function in creativity and be strict with the
examination standard in utility. Only if the patent application possesses the
certain utilities or functions proven by scientific experimentation, will they be
regarded as patentable. In 2002, the United States Patent and Trademark Office
(USPTO) issued guidelines on how it applies patent criteria to different types of
inventions. These guidelines focus on some of subtle distinctions that the
USPTO is called upon to make. Similar interpretative guidelines should be
developed in China with the assistance of an expert panel, and the detailed
operating rules may be stipulated in the guidelines. The guidelines should be
updated on a regular basis and should provide direction to applicants and
examiners, notably on:
(a) the interpretation of the criteria for issuing a patent (i.e., breadth of
claims, novelty, utility and non-obviousness) as they relate to biological
inventions, and
(b) the process to be followed by patent applicants and the benchmark time
frames for each step, to the extent (if any) that these may differ from
other patent applications.
107
BIBLIOGRAPHY
i. LEGISLATION:
a). International:
Convention on Biological Diversity, D.N.T.S., June 5 1992, online:
<http://www.biodiv.arg.>
General Agreement on Tariffs and Trade, October 30 1947, 58 D.N.T.S. 187, online:
WTO <http://www.wto.org>.
Universal Declaration on the Human Genome and Human Rights, U.N.T.S., September
9 1998, online: United Nations Education, Scientific and Cultural Organization<http://
www.unesco.org>.
WTO's Agreement on the Trade Related Aspects of the Intellectual Property Rights,
WTO, April 15 1994, online: WTO <http://www.wto.org/>.
b). Regional:
European Patent Convention, Administrative Council of European Patent Organization
(Munich: EC, 1973).
European Directive for the Legal Protection of Biotechnological Inventions, EC,
[1998], OJ.L. 213/13.
c). National:
Canada. Canadian Patent Act. RSC 1985.
China. Chinese Contract Act. 2001.
China. Chinese Interim Measure for the Administration of Human Genetic Resources.
1998.
China. Chinese Patent Law. 1985, 1993 and 2001.
108
United States Patent and Trademark Office. "Revised Interim Utility Guidelines For
Examination of Patent Applications Under 35 U.S.c. 112 "Written Description
Requirement", 64 Fed. Reg. 71,427 (Dec. 21, 1999)
United States of America, Patent Act, 35 USc. 1999.
ii. CASE LA W:
Amgen Inc v. Chugai Pharmaceutical Co. Ltd. and Genetics Institute, 927 F. 2d 1200,
18 U.S.P.Q. 2d 1016 (Fed. Cir. 1991).
Brenner v. Manson, 383 U.S.519, 534-35, 148 U.S.P.Q. 689,685 (1966).
Davis v. Davis, 842 SW 588 (Tenn.1992).
Diamond v. Chakrabarty, 447 U.S.303, 206 U.S.P.Q. 193 (1980).
Enzo Biochem, Inc. v. Calgene, Inc., 188 F.3d 1362, 52 U.S.P.Q. 2d 1129 (Fed. Cir.
1999).
Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 1948.
Genentech v. Novo Nordisk, 108 F.3d 1046,29 U.S.P.Q. 2d 2010 (Fed. Cir. 1993).
Harvard College v. Canada (Commissioner of Patents), 2002 SCC 76.
Hect v Superior Court (Kane), 20 Cal. Rptr. 2d 281-283. (Ct. App. 1993).
In re Bell, 1991 F.2d 781 782.26 U.S.P.Q. 2d 1529, 1531 (Fed. Cir. 1993).
In re Deuel, 34 51F. 3d 1552, 34 U.S.P.Q .2d 1210 (Fed. Cir.1995).
In re Goodman, 11 F.3d 1046,1052,29 U.S.P.Q. 2d 2010,2015 (Fed. Cir.1993).
In re Vaeck, 947 F. 2d 488,20 U.S.P.Q.2d 1438 (Fed. Cir. 1991).
In re Wands, 858 F.2d 731,737,8 U.S.P.Q.2d 1400, 1404 (Fed. Cir. 1988).
In re Wright, 999 F.2d 1557, 27 U.S.P.Q.2d 1510 (Fed. Cir. 1993).
109
Juicy Whip, Inc. v. Orange Band Inc., 185 F. 3d 1364 (Fed. Cir. 1999).
Moore v. The Regents of the University of California, 793 P.2d 479 (Cal. 1990).
Nelson v. Bowler, 626 F.2d 853,856,206 U.S.P.Q. 881,883 (C.C.P.A. 1980).
Newman v. Quigg, 877 F. 2d 1575, 1581,11 U.S.P.Q. 2d 1340, 1345 (Fed. Cir. 1989).
T356/93 Plant Genetic Systems, OJ EPO 1995.
V08/94 Howard Florey Institute/ Relaxin, OJ EPO 1995.
T296/93 HVB antigen production! Biogen OJ EPO 627 (1995).
T2/83 OJ EPO 265 (1984), T7/ 86 OJ EPO 381 (1988).
iii. LITERATURE:
a). Books:
A. S. Moraczewski, eds., Genetic Medicine and Engineering-Ethical and Social
Dimensions. (St-Louis: The Catholic Health Association of the United States and The
Pope John XXIII Medical-Moral Research and Education Center,1983).
B. Alberts, Molecular Biology ofthe Cell (New York: Garland Science, 2002).
B. D. Davis, The Genetic Revolution. (Baltimore and London: The Johns Hopkins
University Press, 1991).
B. M. Knoppers, Human Dignity and Genetic Heritage (Ottawa: Law Reform
Commission of Canada 1991).
B. M. Knoppers, C. M. Laberge, and M. Hirtle, Human DNA Law and Policy. (Boston:
Kluwer Law International, 1997).
B. M. Knoppers, T. Caulfield, and T. D. Kinsella, Legal Rights and Human Genetic
Material. (Canada: Emond Montgomery Publication Limited, 1996.)
110
B. M. Knoppers, eds., Droit, Biotechnologies et Societe (Medecine moderne)
(Montreal: COOP DROIT, Universite de Montreal, 2000.)
Bull, Housser and Tupper, Patents, Copyright, Trademarks, and Trade Secrets.
(Ontario: Insight Press, 1990).
Ciba Foundation Symposia, Human Genetic Information: Science, Law and Ethics
(Chichester: John Wiley & Sons Ltd., 1989).
D. J. Kevles and L. Hood, The Code of Codes (Massachusetts: Harvard University
Press, 1992).
D. Suzuki, P. Knudtson, Genetics: the clash between the new genetics and human
values (Massachusetts: Harvard University Press, 1990).
F. Dessemontet, Le genie genetique: Biotechnology and Patent Law (Paris: Cedidac,
1996).
G. J. Annas, S. Elias, Gene Mapping (New York: Oxford University Press, 1992).
G. Karp, Cell and Molecular Biology (New York: John Wiley & Sons, Inc., 1996).
G. Paterson, A Concise Guide to European Patents: laws and practice (London: Sweet
& Maxwell, 1995).
H. R. Jaenichen, The European Patent Office's Case Law On the Patentability of
Biotechnological Inventions (Koln: C. Heymanns, 1997).
Health Council of the Netherlands, Committee on Human Tissue for Special Purposes,
Proper use ofHuman Tissue (Hague: Health Council of the Netherlands, 1994).
J. H. Gibbons, Mapping Our Genes (Baltimore: The Johns Hopkins University Press,
1988).
111
L. Walters and J. G. Palmer, The Ethics of Human Gene Therapy (New York: Oxford
University Press, 1997).
L. Kass, Toward a More Natural Science: Biology and Human Affairs (New York: The
Free Press, 1985).
Liu Chuntian, Intellectual Property Law (Beijing: China People's University Press,
2000).
M. A. Rothstein, Genetic Secrets: Protecting Privacy and Confidentiality in the Genetic
Era (New Haven and London: Yale University Press, 1997).
M. S. Frankel and A. H. Teich, The Genetic Frontier Ethics, Law, and Policy
(Washington: American Association for the Advancement of Science, 1994).
W. Harold, Biotechnology Patents: A business, manager's legal guide (Washington:
The Bureau of National Affairs Inc. 1989).
Y. Gendreau, E. Mackaay, Canadian Legislation on Intellectual Property (Toronto:
Carswell,2001).
Z.L. Chen and D. Ming, Copying Lives: Human Beings and Clone (Beijing: Popular
Science Press, 1999).
b). Articles:
B. M. Knoppers, "Status, sale and patenting of human genetic material: an international
survey". (1999) 22 Nature Genetics, at 23-26.
Biotechnology Industry Organization, Encouraging Development of the Biotechnology
Industry: A Best Practices Survey of State Efforts. [March 2000].[database online]
Available: HTTP: http://www.bio.org/govt/ethics.html.
112
Canadian Biotechnology Advisory Committee, Patenting ofhigher life forms (Ottawa:
Canadian Biotechnology Advisory Committee, June 2002).
Canadian Biotechnology Advisory Committee. Patenting of higher life forms and
related issues: report to the Government of Canada Biotechnology Ministerial
Coordinating Committee (Ottawa: Canadian Biotechnology Advisory Committee,
2003).
C. J. Miller, "Patent Law and Human Genomics" (1997) 26 The Capital University
Law Review. 911.
D. Bulter and S. Goodman, "French Researchers Take a Stand Against Cancer Gene
Patent" (2001) 413 Nature. 95-96.
Dr M. Grund and Dr V. Vossius, "Patentability of ESTs under the EPC" (March 1998)
Bio Science Law Review. 106-109.
Ernst & Young, "Convergence: Ernst & Young's Biotechnology Industry Report,
Millennium Edition" (2000), online: Ernst & Young
<http://www.ey.com/industrylhealth>.
European Patent Office, Japan Patent Office and United States Patent Trademark
Office, "Trilateral Project 24.1: Report on Comparative Study on Biotechnology Patent
Practices" (2001), online: EPO http://www.european-patent-office.gov/tws/sr-3-
bio.htm.
Division of Human Science, Philosophy and the Ethics of Science and Technology of
UNESCO, Intellectual Property in the Field of the Human Genome (Paris: UNESCO
Headquarters, 2001).
113
Greenpeace, "Facts about the European Patent Office" (May 1999), online:
Greenpeace<http://www. greenpeace.orglreports>.
H. Smith," Challenge to the Biotechnology Directive" (March 2002) 24, European
Intellectual Propriety Review. 149-154.
H. Ren, "Some Legal Issues on Patenting the Gene Discovery"(March 8, 2001), online:
Beijing University Law Journal <http//www.chinalawinfo.com>
HUGO Ethics Committee, "Statement on Benefit-Sharing" (April 9 2000), online:
HUGO<http://www.hugo_international.orgihugo/benefit.html>.
HUGO Intellectual Property Rights Committee, "HUGO Statement on Patenting of
DNA Sequences-In Particular Response to the European Biotechnology Directive"
(2000), online: HUGO<http://www.hugo.international.org>.
J. Kluger, "Who owns our genes?" (1999) TIME,35.
J. Van Brunt, "A Superlative Year" (2001), online: Signals Magazine
<http://www.signalsmag.com>.
J. V. Brunt, "Biotech Patent Fights"(October 2002), online: Signals Magazine
<http://www.signalsmag.com>.
Jin Ju. 2001, "Life Science and Biotechnology in China"(June 2001), online: Beijing
University Law Journal <http://www.chinagate.com.cnlDEVELOPMENTchina
GATEWAY.htm>.
J. Niosi and Tomas G. Bas, "The Competencies of Regions Canada's Clusters in
biotechnology" (December 1999),
<http://www.wabio.com/industry/econ_dev/CanadaClusterStudy.pdf.>
online:
114
J. Erratt, K. Sechley, G. Strathy and Henderson, "The European Biotechnology
Directive and the Patentability of Higher Life Forms (2000) Journal of Canadian
Biotechnology.
lain C. Baille, J. Richarks and J. Cord, "Biotechnology and United States Patent
Practice"(July 1996), online: Ladas & Parry Intellectual Property Law
<http://www.ladas.com/patents/Biotechnology/Biotechnology.USA.html>.
L. Yan, "Special Subject on Gene" (September 18, 2001), online: Beijing University
Law Journa1<http//www.chinalawinfo.com>
Lu Bingbin, "The Protection of Gene Patent and Ethics"(August 21 2001), online:
http//211.100.18.62/research/academy.
M. S. Tuscan and R. G. Adler, "Patenting of Expressed Sequence Tags in United
States" (1998/1999) 4 Bio Science Law Review. 175-178.
M.S. Greenfield, "Recombinant DNA Technology: A science Struggling with Patent
Law" (May 1992) 44 Stanford Law Review. 1051-1094.
T. Schrecker, C. Elliott, C. Barry Hoffmaster, E.W. Keyserlingk, and M. A. Somerville,
"Ethical Issues Associated with the Patenting of Higher Life Forms" (1997), online:
Industry Canada<http://www.strategis.ic.qc.ca/>.
The British Group of AIPPI, "Patentability Requirements and Scope of Protection of
ESTs, SNPs and Entire Genomes" (2000) 22 European Intellectual Property Review, at
39-45.
Zhang Qinggeng, "The Protection of Biotechnology in China" (November 6, 2000),
online: Beijing University Law Journal <http//www.chinagenenet.com>.
